

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3442745

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
DENDREON CORPORATION, AND ITS WHOLLY OWNED SUBSIDIARIES, DENDREON HOLDINGS, LLC, DENDREON DISTRIBUTION, LLC, AND DENDREON MANUFACTURING, LLC		02/23/2015
RECEIVING PARTY DATA		
Name:	DRONE ACQUISITION SUB INC.	
Street Address:	400 SOMERSET CORPORATE BOULEVARD	
City:	BRIDGEWATER	
State/Country:	NEW JERSEY	
Postal Code:	08807	
PROPERTY NUMBERS Total: 208		
Property Type	Number	
PCT Number:	US1996020241	
Patent Number:	6080409	
Application Number:	08823008	
Patent Number:	5976546	
Patent Number:	6210662	
Patent Number:	4927749	
Patent Number:	4927750	
PCT Number:	US1987000628	
Patent Number:	7413869	
PCT Number:	US1995011169	
Patent Number:	5474687	
Patent Number:	5663051	
Patent Number:	5789148	
Application Number:	09128643	
PCT Number:	US1996019713	
PCT Number:	US1998002661	
Application Number:	08800687	
Patent Number:	6197579	
PCT Number:	US1995011162	

PATENT

Property Type	Number
Patent Number:	5577513
Patent Number:	6015843
PCT Number:	US1999000403
Application Number:	60193504
PCT Number:	US2001010515
Patent Number:	7060279
Patent Number:	7659117
Application Number:	60056110
Patent Number:	6194152
PCT Number:	US1998017058
Application Number:	60773435
Patent Number:	7741355
PCT Number:	US2007004053
Patent Number:	7772266
PCT Number:	US2008083810
Patent Number:	8614243
Patent Number:	8618155
Application Number:	60497384
Patent Number:	8362264
PCT Number:	US2004026931
Patent Number:	8389730
Application Number:	13682151
Application Number:	60220108
Patent Number:	7012066
PCT Number:	US2001022678
Patent Number:	7244721
PCT Number:	US2003001430
Application Number:	11241656
Patent Number:	7592316
Application Number:	12973020
Application Number:	13068159
Application Number:	60220109
Patent Number:	6800434
PCT Number:	US2001022826
Application Number:	10934141
Application Number:	60220101
Application Number:	09909164
PCT Number:	US2001023169

Property Type	Number
Application Number:	60220107
Patent Number:	7169760
PCT Number:	US2001022813
Patent Number:	7595299
PCT Number:	US2014054413
Application Number:	61874279
Application Number:	61892373
Application Number:	14479084
Application Number:	60837209
Patent Number:	7972602
PCT Number:	US2007075681
Patent Number:	8263757
Application Number:	13587619
Application Number:	60837053
Patent Number:	8361479
PCT Number:	US2007075704
Application Number:	60453131
Patent Number:	7597894
PCT Number:	US2004006979
Application Number:	12573685
Application Number:	60112324
Patent Number:	7148324
PCT Number:	US1999029724
Patent Number:	7560104
PCT Number:	US2005045755
Application Number:	60637859
Application Number:	60706467
Patent Number:	7572444
Application Number:	60436264
Patent Number:	7019019
PCT Number:	US2003040927
Application Number:	60021874
Patent Number:	5998599
PCT Number:	US1997011341
Application Number:	60896461
Patent Number:	8153120
PCT Number:	US2008003755
Application Number:	13443703

Property Type	Number
Patent Number:	5648223
Patent Number:	5646004
Patent Number:	5840502
Patent Number:	6797504
PCT Number:	US2001028137
Patent Number:	7157596
Patent Number:	6576613
Patent Number:	6432922
PCT Number:	US1999016577
Patent Number:	5371072
Patent Number:	5597804
PCT Number:	US1993010015
Patent Number:	5869454
Application Number:	60098292
Application Number:	09383663
PCT Number:	US1999019628
Patent Number:	6416958
Application Number:	60608944
Patent Number:	8354507
PCT Number:	US2004042312
Patent Number:	5714499
Patent Number:	5932733
Application Number:	08484260
PCT Number:	US1995007832
Application Number:	08261378
Application Number:	08480475
Patent Number:	5703208
Application Number:	08487007
PCT Number:	US1995007661
Application Number:	08356831
Patent Number:	6034215
Application Number:	07601454
Patent Number:	5506134
PCT Number:	US1991007811
Application Number:	08163576
Patent Number:	5843442
Patent Number:	6221659
Application Number:	07913232

Property Type	Number
Application Number:	07952801
Patent Number:	5807980
Patent Number:	5747449
PCT Number:	US1993006530
Application Number:	08456754
Patent Number:	5776927
Patent Number:	5681844
Patent Number:	5658939
PCT Number:	US1995004954
Patent Number:	5646165
Patent Number:	5770600
Application Number:	09021663
Patent Number:	7132398
PCT Number:	US2004013942
Patent Number:	7329640
Application Number:	10440475
PCT Number:	US2004015100
Patent Number:	7279309
Application Number:	11818324
Application Number:	60337100
Patent Number:	7262211
PCT Number:	US2002038788
Application Number:	07991204
Patent Number:	5883077
PCT Number:	US1993012255
Patent Number:	5739112
Patent Number:	5747296
PCT Number:	US1993012626
Application Number:	08450492
Patent Number:	6756211
Patent Number:	6962795
Patent Number:	5708141
Patent Number:	5919900
Patent Number:	6818616
Application Number:	08458216
Patent Number:	5789178
Patent Number:	6777431
Patent Number:	5696231

Property Type	Number
Patent Number:	6025472
Application Number:	60291001
Patent Number:	7112430
PCT Number:	US2002015332
Application Number:	60278166
Patent Number:	7172892
PCT Number:	US2002009039
Application Number:	60279228
Patent Number:	7105333
PCT Number:	US2002009611
Application Number:	60183542
Application Number:	60213124
Application Number:	60222970
Application Number:	60234840
Patent Number:	7700341
PCT Number:	US2001003471
Patent Number:	7888092
Application Number:	12927372
Application Number:	60275592
Patent Number:	7125703
PCT Number:	US2002007903
Application Number:	60166391
PCT Number:	US2000031803
Patent Number:	7276364
Patent Number:	6638977
Application Number:	60185564
Patent Number:	6677473
Patent Number:	6121044
PCT Number:	US1996011640
Patent Number:	6787612
PCT Number:	US1999016828
Patent Number:	6011047
PCT Number:	US1998025167
Application Number:	07828388
Patent Number:	5534498
PCT Number:	US1993000906
Patent Number:	5714580

CORRESPONDENCE DATA**Fax Number:** (585)232-2152*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 585-231-1286**Email:** jthomas@hselaw.com**Correspondent Name:** JOHN E. THOMAS, ESQ.**Address Line 1:** 1600 BAUSCH & LOMB PLACE**Address Line 4:** ROCHESTER, NEW YORK 14604-2711

ATTORNEY DOCKET NUMBER:	100277.000012
NAME OF SUBMITTER:	JOHN E. THOMAS
SIGNATURE:	/John E Thomas/
DATE SIGNED:	07/16/2015

Total Attachments: 32

source=100277-12_Dendreon_Assignment#page1.tif
source=100277-12_Dendreon_Assignment#page2.tif
source=100277-12_Dendreon_Assignment#page3.tif
source=100277-12_Dendreon_Assignment#page4.tif
source=100277-12_Dendreon_Assignment#page5.tif
source=100277-12_Dendreon_Assignment#page6.tif
source=100277-12_Dendreon_Assignment#page7.tif
source=100277-12_Dendreon_Assignment#page8.tif
source=100277-12_Dendreon_Assignment#page9.tif
source=100277-12_Dendreon_Assignment#page10.tif
source=100277-12_Dendreon_Assignment#page11.tif
source=100277-12_Dendreon_Assignment#page12.tif
source=100277-12_Dendreon_Assignment#page13.tif
source=100277-12_Dendreon_Assignment#page14.tif
source=100277-12_Dendreon_Assignment#page15.tif
source=100277-12_Dendreon_Assignment#page16.tif
source=100277-12_Dendreon_Assignment#page17.tif
source=100277-12_Dendreon_Assignment#page18.tif
source=100277-12_Dendreon_Assignment#page19.tif
source=100277-12_Dendreon_Assignment#page20.tif
source=100277-12_Dendreon_Assignment#page21.tif
source=100277-12_Dendreon_Assignment#page22.tif
source=100277-12_Dendreon_Assignment#page23.tif
source=100277-12_Dendreon_Assignment#page24.tif
source=100277-12_Dendreon_Assignment#page25.tif
source=100277-12_Dendreon_Assignment#page26.tif
source=100277-12_Dendreon_Assignment#page27.tif
source=100277-12_Dendreon_Assignment#page28.tif
source=100277-12_Dendreon_Assignment#page29.tif
source=100277-12_Dendreon_Assignment#page30.tif
source=100277-12_Dendreon_Assignment#page31.tif
source=100277-12_Dendreon_Assignment#page32.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Patent Assignment") is entered into as of February 23, 2015 (the "Effective Date"), by and among Dendreon Corporation, a Delaware corporation, having an address at 1301 2nd Avenue, Seattle, Washington 98101 (the "Parent"), its wholly owned subsidiaries, Dendreon Holdings, LLC, Dendreon Distribution, LLC, and Dendreon Manufacturing, LLC, each a Delaware limited liability company and each having an address at 1301 2nd Avenue, Seattle, Washington 98101 (together with the Parent, the "Sellers") and Drone Acquisition Sub Inc., a Delaware corporation, having an address at 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807 (the "Purchaser").

RECITALS

WHEREAS, the Sellers, Valeant Pharmaceuticals International, Inc. and the Purchaser have entered into that certain Second Amended and Restated Acquisition Agreement, dated as of February 19, 2015 (the "Acquisition Agreement"), pursuant to which, among other things, the Sellers have agreed to sell, assign, transfer, convey and deliver to the Purchaser all right, title and interest of the Sellers in and to the Assigned Patents (as defined below), and the Purchaser has agreed to purchase and accept all right, title and interest of the Sellers in and to the Assigned Patents from the Sellers.

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Assigned Patents. "Assigned Patents" means the patents and patent applications listed on Schedule 1 attached hereto, together with any continuations, continuations-in-part, divisionals, substitutions, reissues, reexaminations, extensions, foreign equivalents and supplementary protection certificates of any of the foregoing listed on Schedule 1.

2. Assignment. Each of the Sellers does hereby sell, assign, transfer, convey and deliver to the Purchaser all right, title and interest of the Sellers in and to the Assigned Patents for the Purchaser's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Sellers if this Patent Assignment and sale had not been made, together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, the right to sue and recover damages for past, present and future infringement of any of the Assigned Patents.

3. Recordation. Each of the Sellers hereby requests and authorizes the Commissioner of Patents and Trademarks, and any other applicable governmental entity, to record the Purchaser as the owner of the Assigned Patents, as assignee of the entire right, title and interest in and to the same. The Purchaser shall have the right to record this Patent

Assignment with all applicable governmental entities so as to perfect its ownership of the Assigned Patents.

4. Counterparts. This Patent Assignment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement. A faxed or electronic (i.e., PDF) signature shall be deemed original for all purposes under this Patent Assignment.

5. Further Assurances. Each of the parties hereto agrees to execute and deliver such documents, and to take such actions, as may be reasonably requested by the other party to give effect to this Patent Assignment and to vest, perfect, confirm, record or otherwise reflect the parties' rights as set forth herein.

6. Governing Law; Submission of Jurisdiction; Waiver of Jury Trial. This Patent Assignment shall be governed by and construed in accordance with the laws of the State of Delaware without regard to the rules of conflict of laws of the State of Delaware or any other jurisdiction. Each of the parties hereto irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") for any litigation arising out of or relating to this Patent Assignment and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in the Bankruptcy Court), and waives any objection to the laying of venue of any such litigation in the Bankruptcy Court. Each party hereto hereby consents to service of process in the manner and at the address set forth in Section 8.5 of the Acquisition Agreement. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION ARISING OUT OF OR RELATING TO THIS PATENT ASSIGNMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the undersigned have caused this Patent Assignment to be duly executed and delivered as of the date first set forth above.

SELLERS:

DENDREON CORPORATION


By: 
Name: Robert L. Crotty
Title: Executive Vice President,
General Counsel and Secretary

State of NEW JERSEY
County of MERCER

RAKESH PATEL
NOTARY PUBLIC
STATE OF NEW JERSEY


On February 21st, 2015, before me, MY COMMISSION EXPIRES OCT. 4, 2019, Notary Public in an said county, personally appeared, Robert L. Crotty, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to be the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.


Notary Public

(Signature Page to Patent Assignment)

DENDREON HOLDINGS, LLC


By: 
Name: Robert L. Crotty
Title: Vice President,
General Counsel and Secretary

State of NEW JERSEY
County of MERCER

RAKESH PATEL
NOTARY PUBLIC
STATE OF NEW JERSEY
MY COMMISSION EXPIRES OCT. 4, 2019

On February 21st, 2015, before me, _____, Notary Public in an said county, personally appeared, Robert L. Crotty, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to be the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.


Notary Public

(Signature Page to Patent Assignment)

DENDREON DISTRIBUTION, LLC

By: 
Name: Robert L. Crotty
Title: Vice President,
General Counsel and Secretary

State of NEW JERSEY
County of MERSEN

RAKESH PATEL
NOTARY PUBLIC
STATE OF NEW JERSEY

On February 21st, 2015, before me, MY COMMISSION EXPIRES OCT. 4, 2019, Notary Public in an said county, personally appeared, Robert L. Crotty, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to be the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.


WITNESS my hand and official seal.



Notary Public

(Signature Page to Patent Assignment)

DENDREON MANUFACTURING, LLC

By: 
Name: Robert L. Crotty
Title: Vice President,
General Counsel and Secretary

State of NEW JERSEY
County of MERIDEN

RAKESH PATEL
NOTARY PUBLIC

On February 21st, 2015, before me, ~~STATE OF NEW JERSEY~~, Notary Public in an
said county, personally appeared, Robert L. Crotty, MY COMMISSION EXPIRES OCT. 4, 2019, who proved to me on
the basis of satisfactory evidence to be the person whose name is subscribed to be the within
instrument and acknowledged to me that he executed the same in his authorized capacity, and
that by his signature on the instrument the person, or the entity upon behalf of which the person
acted, executed the instrument.


WITNESS my hand and official seal.


Notary Public

(Signature Page to Patent Assignment)

PURCHASER:


DRONE ACQUISITION SUB INC.


By: 
Name: Robert R. Chai-Onn
Title: Executive Vice President, General Counsel

State of New Jersey)
County of Morris)

On February 21, 2015, before me, Kaleena T. Nguyen, Notary Public in an said county, personally appeared, Robert R. Chai-Onn, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to be the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.


Notary Public



(Signature Page to Patent Assignment)

PATENT
REEL: 036126 FRAME: 0272

Schedule 1

Assigned Patents

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015 Page 1

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
PROVENGE Specific Patent Families Highlighted in Red							
IMMUNOSTIMULATORY METHOD							
AUSTRIA	14-122-005AT	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
AUSTRALIA	14-122-005AU	DCA	12/23/1996	13380/97	6/22/2000	716783	ISSUED
BELGIUM	14-122-005BE	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
CANADA	14-122-005CA	DCA	12/23/1996	2,241,373	4/9/2013	2,241,373	ISSUED
DENMARK	14-122-005DK	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
EUROPEAN PATENT	14-122-005EP	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
SPAIN	14-122-005ES	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
FINLAND	14-122-005FI	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
FRANCE	14-122-005FR	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
UNITED KINGDOM	14-122-005GB	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
GREECE	14-122-005GR	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
IRELAND	14-122-005IE	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
ITALY	14-122-005IT	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
JAPAN	14-122-005JP	DCA	12/23/1996	9-524418	1/26/2007	3908277	ABANDONED
LUXEMBOURG	14-122-005LU	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
MONACO	14-122-005MC	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
NETHERLANDS	14-122-005NL	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
NEW ZEALAND	14-122-005NZ	DCA	12/23/1996	328092	3/9/2000	328092	ISSUED
PORTUGAL	14-122-005PT	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
SWEDEN	14-122-005SE	DCA	12/23/1996	96944879.4	2/7/2007	870022	ISSUED
WIPO	14-122-005WO	CEQ	12/23/1996	PCT/US96/20241	7/10/1997	WO97/24438	NAT PHASE
UNITED STATES	14-122-005US	NEW	12/28/1995	08/579,823	6/27/2000	6,080,409	ISSUED
UNITED STATES	14-122-005US DIV	DIV	3/21/1997	08/823,008			ABANDONED
UNITED STATES	14-122-005US DIV1	DIV	9/3/1998	09/146,283	11/2/1999	5,978,548	ISSUED
UNITED STATES	14-122-005US CON	CON	6/24/1999	09/344,195	4/3/2001	6,210,862	ISSUED
NEW ZEALAND	14-122-005NZ DIV	DIV	10/28/1999	500665	10/6/2005	500665	ISSUED
SWITZERLAND	14-122-005CH	DCA	10/6/2000	00968813.6	2/7/2007	870022	ISSUED
GERMANY	14-122-005DE	DCA	12/23/2006	96944879.4	2/7/2007	870022	ISSUED

REAGENT FOR CELL SEPARATION

CANADA	14-123-002CA	DCA	3/25/1987	534,167	7/30/1996	1,338,492	EXPIRED
JAPAN	14-123-002JP	DCA	3/25/1987	82-502184	4/18/1997	2828509	EXPIRED
UNITED STATES	14-123-002US	NEW	4/9/1986	06/849,819	5/22/1990	4,927,749	EXPIRED
UNITED STATES	14-123-002US CIP	CIP	3/25/1987	07/049,863	5/22/1990	4,927,750	EXPIRED
WIPO	14-123-002WO	CEQ	3/25/1987	PCT/US87/00628			NAT PHASE

METHOD FOR DETERMINING POTENCY OF ANTIGENIC PRESENTING CELL BASED VACCINES

UNITED STATES	14-123-007US	NEW	4/5/2002	10/118,392	8/19/2008	7,413,869	ISSUED
---------------	--------------	-----	----------	------------	-----------	-----------	--------

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 2

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
CELL SEPARATION COMPOSITION, KIT AND METHOD							
AUSTRIA	14-123-001AT	DCA	8/31/1995	95831685	5/10/2000	0778944	ISSUED
AUSTRALIA	14-123-001AU	DCA	8/31/1995	35025/95	3/22/1996	700743	ISSUED
CANADA	14-123-001CA	DCA	8/31/1995	2,198,607	4/18/2000	2,198,607	ISSUED
SWITZERLAND	14-123-001CH	DCA	8/31/1995	19950931685	2/2/2000	0778944	ISSUED
GERMANY	14-123-001DE	DCA	8/31/1995	89513188.5	7/6/2000	DE69613188T2	ISSUED
DENMARK	14-123-001DK	DCA	8/31/1995	EP19950931685	5/1/2000	DK/EP 0778944	ISSUED
EUROPEAN PATENT	14-123-001EP	DCA	8/31/1995	EP19950931685	11/3/1999	EP0778944	ISSUED
SPAIN	14-123-001ES	DCA	8/31/1995	95031685.2	3/1/2000	ES2140706T3	ISSUED
FRANCE	14-123-001FR	DCA	8/31/1995	95831685.2	11/3/1999	0778944	ISSUED
UNITED KINGDOM	14-123-001GB	DCA	8/31/1995	EP19950931685	11/3/1999	EP0778944	ISSUED
HONG KONG	14-123-001HK	DCA	8/31/1995	98115108.0	10/15/2000	HK1013862	ISSUED
IRELAND	14-123-001IE	DCA	8/31/1995	EP19950931685	11/3/1999	EP0778944	ISSUED
ITALY	14-123-001IT	DCA	8/31/1995	EP19950931685	1/17/2000	671448E/2000	ISSUED
JAPAN	14-123-001JP	DCA	8/31/1995	8-508995	2/14/2003	3397795	ISSUED
NETHERLANDS	14-123-001NL	DCA	8/31/1995	95831685.2	12/29/1999	0778944	ISSUED
NEW ZEALAND	14-123-001NZ	DCA	8/31/1995	PCT/US95/11169	2/11/1999	292756	ISSUED
SWEDEN	14-123-001SE	DCA	8/31/1995	95831685.2	11/3/1999	0778944	ISSUED
WIPO	14-123-001WO	CEQ	8/31/1995	PCT/US95/11169		WO98/07097	NAT PHASE
UNITED STATES	14-123-001US	NEW	3/31/1994	08/289,469	12/12/1995	5,474,687	EXPIRED
UNITED STATES	14-123-001US CIP	CIP	12/11/1995	08/570,397	9/2/1997	5,663,051	EXPIRED
UNITED STATES	14-123-003US CIP	CIP	12/11/1995	08/570,120	8/4/1998	5,789,148	EXPIRED
UNITED STATES	14-123-003US CON	CON	8/4/1996	09/128,643			ABANDONED
AUSTRIA	14-123-003AT	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
AUSTRALIA	14-123-003AU	DCA	12/11/1996	14150/97	11/4/1999	707878	ISSUED
BELGIUM	14-123-003BE	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
CANADA	14-123-003CA	DCA	12/11/1996	2,239,729	10/31/2006	2,239,729	ISSUED
SWITZERLAND	14-123-003CH	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
CYPRUS	14-123-003CY	DCA	12/11/1996	96944310.0	10/26/2011	958046	INACTIVE
GERMANY	14-123-003DE	DCA	12/11/1996	96944310.0	10/26/2011	958046 /596 38 439.6	ISSUED
DENMARK	14-123-003DK	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
EUROPEAN PATENT	14-123-003EP	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
SPAIN	14-123-003ES	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
FINLAND	14-123-003FI	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
FRANCE	14-123-003FR	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
UNITED KINGDOM	14-123-003GB	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
GREECE	14-123-003GR	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
HONG KONG	14-123-003HK	DCA	12/11/1996	96944310.0	3/23/2012	1023083	ISSUED
IRELAND	14-123-003IE	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
ITALY	14-123-003IT	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
JAPAN	14-123-003JP Div	DIV		2006-117292			ABANDONED
JAPAN	14-123-003JP	DCA	12/11/1996	9-522180	8/3/2007	3993892	ABANDONED
LUXEMBOURG	14-123-003LU	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
MONACO	14-123-003MC	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
NETHERLANDS	14-123-003NL	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
PORTUGAL	14-123-003PT	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
SWEDEN	14-123-003SE	DCA	12/11/1996	96944310.0	10/26/2011	958046	ISSUED
WIPO	14-123-003WO	CEQ	12/11/1996	PCT/US96/19713	6/19/1997	WO 97/21488	NAT PHASE

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 3

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
CELL WASHING DEVICE AND METHOD							
AUSTRIA	14-123-004AT	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
AUSTRALIA	14-123-004AU	DCA	2/13/1998	61581/98	3/7/2002	741086	ISSUED
BELGIUM	14-123-004BE	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
CANADA	14-123-004CA	DCA	2/13/1998	2,280,129	10/24/2006	2,280,129	ISSUED
SWITZERLAND	14-123-004CH	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
GERMANY	14-123-004DE	DCA	2/13/1998	69819689.9-08	11/12/2003	0959989	ISSUED
DENMARK	14-123-004DK	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
EUROPEAN PATENT	14-123-004EP	DCA	2/13/1998	98906333.4	11/12/2003	0959989	ISSUED
SPAIN	14-123-004ES	DCA	2/13/1998	98906333.4	11/21/2003	0959989	ISSUED
FINLAND	14-123-004FI	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
FRANCE	14-123-004FR	DCA	2/13/1998	98906333.4	11/21/2003	0959989	ISSUED
UNITED KINGDOM	14-123-004GB	DCA	2/13/1998	98906333.4	11/21/2003	0959989	ISSUED
GREECE	14-123-004GR	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
IRELAND	14-123-004IE	DCA	2/13/1998	98906333.4	11/21/2003	0959989	ISSUED
ITALY	14-123-004IT	DCA	2/13/1998	98906333.4	11/21/2003	0959989	ISSUED
JAPAN	14-123-004JP	DCA	2/13/1998	10-535874	11/12/2004	3615226	ISSUED
LUXEMBOURG	14-123-004LU	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
MONACO	14-123-004MC	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
NETHERLANDS	14-123-004NL	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
NEW ZEALAND	14-123-004NZ	DCA	2/13/1998	337472	8/9/2001	337472	ISSUED
PORTUGAL	14-123-004PT	DCA	2/13/1998	98906333.4	11/12/2003	EP 0959989	ABANDONED
SWEDEN	14-123-004SE	DCA	2/13/1998	98906333.4	11/12/2003	0959989	ISSUED
WIPO	14-123-004WO	CEO	2/13/1998	PCT/US98/02661		WO 98/035758	NAT PHASE
UNITED STATES	14-123-004US	NEW	2/14/1997	08/800,687			ABANDONED
UNITED STATES	14-123-004US CIP	CIP	7/17/1998	09/118,326	3/6/2001	6,197,579	ISSUED
HONG KONG	14-123-004HK	DCA	5/2/2000	00102655.2			ABANDONED

CENTRIFUGATION SYRINGE, SYSTEM AND METHOD

AUSTRIA	14-122-001AT	DCA	8/31/1995	95931683.7	2/25/1999	0778794	ISSUED
AUSTRALIA	14-122-001AU	DCA	8/31/1995	35023/95	11/13/1997	860363	ISSUED
BELGIUM	14-122-001BE	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
CANADA	14-122-001CA	DCA	8/31/1995	2,198,606	10/17/2000	2,198,606	ISSUED
SWITZERLAND	14-122-001CH	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
GERMANY	14-122-001DE	DCA	8/31/1995	69503512.6	7/15/1998	DE69503512T2	ISSUED
DENMARK	14-122-001DK	DCA	8/31/1995	95931683.7	7/15/1998	DK/EP0778794	ISSUED
EUROPEAN PATENT	14-122-001EP	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
HONG KONG	14-122-001HK	DCA	12/23/1998	98115107.1	6/23/2000	HK1013807	ISSUED
SPAIN	14-122-001ES	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
FRANCE	14-122-001FR	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
UNITED KINGDOM	14-122-001GB	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
GREECE	14-122-001GR	DCA	8/31/1995	95931683.7	12/31/1998	3028114	ISSUED
IRELAND	14-122-001IE	DCA	8/31/1995	95931683.7	1/15/1998	07789794	ISSUED
ITALY	14-122-001IT	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
JAPAN	14-122-001JP	DCA	8/31/1995	8-508994	10/31/2003	3487604	ISSUED
LUXEMBOURG	14-122-001LU	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
MONACO	14-122-001MC	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
NETHERLANDS	14-122-001NL	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
NEW ZEALAND	14-122-001NZ	DCA	8/31/1995	292754	5/12/1999	292754	ISSUED
PORTUGAL	14-122-001PT	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
SWEDEN	14-122-001SE	DCA	8/31/1995	95931683.7	7/15/1998	0778794	ISSUED
WIPO	14-122-001WO	CEO	8/31/1995	PCT/US95/11162	3/7/1996	WO96/06679	NAT PHASE
UNITED STATES	14-122-001US	NEW	8/31/1994	08/298,882	11/26/1996	5,577,513	EXPIRED

Confidential

PATENT
REEL: 036126 FRAME: 0276

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 4

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
PROCESS FOR MAKING SILANIZED COLLOIDAL SILICA							
UNITED STATES	14-123-005US	NEW	1/14/1998	09/006,775	1/18/2000	6,015,843	ISSUED
AUSTRIA	14-123-005AT	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
AUSTRALIA	14-123-005AU	DCA	1/7/1999	22170/99	4/18/2002	742446	ISSUED
BELGIUM	14-123-005BE	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
BRAZIL	14-123-005BR	DCA	1/7/1999	9906965-2	11/4/2008	9906965-2	ISSUED
CANADA	14-123-005CA	DCA	1/7/1999	2,317,488	9/25/2008	2,317,488	ISSUED
SWITZERLAND	14-123-005CH	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
CYPRUS	14-123-005CY	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
GERMANY	14-123-005DE	DCA	1/7/1999	699 06 930 0-08	2/12/2004	DE 699 06 930 T2	ISSUED
DENMARK	14-123-005DK	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
EUROPEAN PATENT	14-123-005EP	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
SPAIN	14-123-005ES	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
FINLAND	14-123-005FI	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
FRANCE	14-123-005FR	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
UNITED KINGDOM	14-123-005GB	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
GREECE	14-123-005GR	DCA	1/7/1999	99902116.5	7/15/2003	3044891	ISSUED
HONG KONG	14-123-005HK	DCA	1/7/1999	00107874.6	10/17/2008	HK1028390	ISSUED
IRELAND	14-123-005IE	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
ITALY	14-123-005IT	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
JAPAN	14-123-005JP	DCA	1/7/1999	2000-540080	8/27/2010	4578046	ISSUED
LUXEMBOURG	14-123-005LU	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
MONACO	14-123-005MC	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
NETHERLANDS	14-123-005NL	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
NEW ZEALAND	14-123-005NZ	DCA	1/7/1999	506157	6/9/2003	506157	ISSUED
PORTUGAL	14-123-005PT	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
SWEDEN	14-123-005SE	DCA	1/7/1999	99902116.5	4/16/2003	1047635	ISSUED
SINGAPORE	14-123-005SG	DCA	1/7/1999	200009671-5	8/30/2002	74405	ISSUED
WIPO	14-123-005WO	CEQ	1/7/1999	PCT/US99/00403		WO99/36359	NAT PHASE

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 5

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
---------	------------	------	-------	---------	--------	---------	--------

DN24-02 Specific Patents Highlighted in Blue

COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY

UNITED STATES	14-124-001US PRV	NEW	3/30/2000	60/193,504			INACTIVE
AUSTRIA	14-124-001AT	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
AUSTRALIA	14-124-001AU	DCA	3/30/2001	2001247919	5/26/2006	2001247919	ISSUED
BELGIUM	14-124-001BE	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
CANADA	14-124-001CA	DCA	3/30/2001	2,403,964	4/30/2013	2,403,964	ISSUED
SWITZERLAND	14-124-001CH	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
CYPRUS	14-124-001CY	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
GERMANY	14-124-001DE	DCA	3/30/2001	01920913.9	4/27/2011	60144516.3	ISSUED
DENMARK	14-124-001DK	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
EUROPEAN PATENT	14-124-001EP	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
SPAIN	14-124-001ES	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
FINLAND	14-124-001FI	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
FRANCE	14-124-001FR	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
UNITED KINGDOM	14-124-001GB	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
GREECE	14-124-001GR	DCA	3/30/2001	01920913.9	6/2/2011	1272633	ISSUED
IRELAND	14-124-001IE	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
ITALY	14-124-001IT	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
JAPAN	14-124-001JP	DCA	3/30/2001	2001-572544	10/19/2012	5110674	ISSUED
LUXEMBOURG	14-124-001LU	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
MONACO	14-124-001MC	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
NETHERLANDS	14-124-001NL	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
NEW ZEALAND	14-124-001NZ	DCA	3/30/2001	522066	12/9/2004	522066	ISSUED
PORTUGAL	14-124-001PT	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
SWEDEN	14-124-001SE	DCA	3/30/2001	01920913.9	4/27/2011	1272633	ISSUED
WIPO	14-124-001WO	CEQ	3/30/2001	PCT/US01/10515		WO 01/74855	NAT PHASE
UNITED STATES	14-124-001US	FOA	3/30/2001	09/621,883	6/13/2006	7,060,279	ISSUED
UNITED STATES	14-124-001US CON	CON	6/3/2005	11/144,912	2/9/2010	7,659,117	ISSUED

Confidential

PATENT
REEL: 036126 FRAME: 0278

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 6

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
TRPM8 Related and D-3263 Specific Patents and Applications Highlighted in Green							
PROSTATE TUMOR POLYNUCLEOTIDE AND ANTIGEN COMPOSITION							
UNITED STATES	14-126-001US PRV	NEW	8/20/1997	80/056,110			INACTIVE
UNITED STATES	14-126-001US	FCA	7/9/1998	09/112,098	2/27/2001	5,194,152	ISSUED
AUSTRALIA	14-126-001AU	DCA	8/18/1998	90218/93	8/20/2002	744875	ISSUED
CANADA	14-126-001CA	DCA	8/18/1998	2,300,304			PENDING
SWITZERLAND	14-126-001CH	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
GERMANY	14-126-001DE	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
EUROPEAN PATENT	14-126-001EP	DCA	8/18/1998	98942089.8		1005549	ISSUED
SPAIN	14-126-001ES	CEQ	8/18/1998	98942089.8	2/13/2008	98942089.8	ISSUED
FRANCE	14-126-001FR	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
UNITED KINGDOM	14-126-001GB	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
HONG KONG	14-126-001HK	DCA	8/18/1998	00107782.1	9/26/2008	1029138	ISSUED
IRELAND	14-126-001IE	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
JAPAN	14-126-001JP	DCA	8/18/1998	2000-509330	12/18/2006	4234919	ISSUED
LUXEMBOURG	14-126-001LU	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
NETHERLANDS	14-126-001NL	CEQ	8/18/1998	98942089.8	2/13/2008	1005549	ISSUED
NEW ZEALAND	14-126-001NZ	DCA	8/18/1998	503404	6/10/2002	503404	ISSUED
WIPO	14-126-001WO	CEQ	8/19/1998	PCT/US99/17068		WO99/09166	NAT PHASE
ITALY	14-126-001IT	CEQ	8/18/2008	98942089.8	2/13/2008	1005549	ISSUED

SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY

UNITED STATES	14-126-003US PRV	NEW	2/15/2006	80/773,435			INACTIVE
AUSTRIA	14-126-003AT	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
BELGIUM	14-126-003BE	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
BULGARIA	14-126-003BG	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
SWITZERLAND	14-126-003CH	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
CYPRUS	14-126-003CY	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
CZECH REPUBLIC	14-126-003CZ	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
GERMANY	14-126-003DE	DCA	1/15/2007	07750861.2	10/2/2013	602007033151.5	ISSUED
DENMARK	14-126-003DK	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
ESTONIA	14-126-003EE	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
EUROPEAN PATENT	14-126-003EP	CEQ	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
SPAIN	14-126-003ES	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
FINLAND	14-126-003FI	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
FRANCE	14-126-003FR	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
UNITED KINGDOM	14-126-003GB	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
GREECE	14-126-003GR	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
HUNGARY	14-126-003HU	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
IRELAND	14-126-003IE	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
ICELAND	14-126-003IS	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
ITALY	14-126-003IT	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
LITHUANIA	14-126-003LT	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
LUXEMBOURG	14-126-003LU	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
LATVIA	14-126-003LV	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
MONACO	14-126-003MC	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
NETHERLANDS	14-126-003NL	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
POLAND	14-126-003PL	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
PORTUGAL	14-126-003PT	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
ROMANIA	14-126-003RO	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
SWEDEN	14-126-003SE	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED
SLOVENIA	14-126-003SI	DCA	1/15/2007	07750861.2	10/2/2013	1986622	ISSUED

Confidential

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 4/16/2014

Page 7

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY continued . . .							
SLOVAK REPUBLIC	14-126-003SK	DCA	1/15/2007	07750881.2	10/2/2013	1988622	ISSUED
TURKEY	14-126-003TR	DCA	1/15/2007	07750881.2	10/2/2013	1988622	ISSUED
AUSTRALIA	14-126-003AU	DCA	2/15/2007	2007215015			PENDING
BRAZIL	14-126-003BR	DCA	2/15/2007	PI0707821-8			PENDING
CANADA	14-126-003CA	DCA	2/15/2007	2642297			PENDING
CHINA	14-126-003CN	CEQ	2/15/2007	200760013155.7			PUBLISHED
EUROPEAN PATENT	14-126-003EP DIV	DIV	2/15/2007	12001852.8			PENDING
INDIA	14-126-003IN	DCA	2/15/2007	3660/KOLNP/2008			PENDING
JAPAN	14-126-003JP	DCA	2/15/2007	2008-565361	10/4/2013	5376957	ISSUED
SOUTH KOREA	14-126-003KR	CEQ	2/15/2007	10-2008-7022583			PUBLISHED
MEXICO	14-126-003MX	DCA	2/15/2007	MX/a/2008/010434	2/15/2012	298249	ISSUED
RUSSIA	14-126-003RU	DCA	2/15/2007	2008138659			PENDING
SINGAPORE	14-126-003SG	DCA	2/15/2007	200806003-0	7/29/2011	145256	ISSUED
TAIWAN	14-126-003TW	CEQ	2/15/2007	98105713	7/11/2013	1401248	ISSUED
UNITED STATES	14-126-003US	FOA	2/15/2007	11/707,546	8/22/2010	7,741,355	ISSUED
WIPO	14-126-003WO	CEQ	2/15/2007	PCT/US07/04053			NAT PHASE
UNITED STATES	14-126-003US CIP	CIP	11/19/2007	11/942,660	8/10/2010	7,772,266	ISSUED
SOUTH AFRICA	14-126-003ZA	DCA	9/5/2008	2008/07680	2/23/2011	2008/07680	ISSUED
CANADA	14-126-003CA CIP	DCA	11/17/2008	2,708,102			PENDING
EUROPEAN PATENT	14-126-003EP CIP	DCA	11/17/2008	08852382.4			PUBLISHED
WIPO	14-126-003WO CIP	CEQ	11/17/2008	PCT/US08/083810			NAT PHASE
HONG KONG	14-126-003HK	CEQ	5/5/2009	09104113.5			PENDING
UNITED STATES	14-126-003US CON	CON	6/8/2010	12/796,587	12/24/2013	8,614,243	ISSUED
UNITED STATES	14-126-003US CIP DIV	DIV	3/9/2010	12/853,202	12/31/2013	8,613,155 B2	ISSUED
JAPAN	14-126-003JP DIV	DIV	1/17/2013	2013-6063			PENDING
SLOVENIA	14-126-003SI	DCA	1/15/2007	07750881.2	10/2/2013	1988622	ISSUED
SLOVAK REPUBLIC	14-126-003SK	DCA	1/15/2007	07750881.2	10/2/2013	1988622	ISSUED
TURKEY	14-126-003TR	DCA	1/15/2007	07750881.2	10/2/2013	1988622	ISSUED
AUSTRALIA	14-126-003AU	DCA	2/15/2007	2007215015			PENDING
BRAZIL	14-126-003BR	DCA	2/15/2007	PI0707821-8			PENDING
CANADA	14-126-003CA	DCA	2/15/2007	2642297			PENDING
CHINA	14-126-003CN	CEQ	2/15/2007	200760013155.7			PUBLISHED
EUROPEAN PATENT	14-126-003EP DIV	DIV	2/15/2007	12001852.8			PENDING
INDIA	14-126-003IN	DCA	2/15/2007	3660/KOLNP/2008			PENDING
JAPAN	14-126-003JP	DCA	2/15/2007	2008-565361	10/4/2013	5376957	ISSUED
SOUTH KOREA	14-126-003KR	CEQ	2/15/2007	10-2008-7022583			PUBLISHED
MEXICO	14-126-003MX	DCA	2/15/2007	MX/a/2008/010434	2/15/2012	298249	ISSUED
RUSSIA	14-126-003RU	DCA	2/15/2007	2008138659			PENDING
SINGAPORE	14-126-003SG	DCA	2/15/2007	200806003-0	7/29/2011	145256	ISSUED
TAIWAN	14-126-003TW	CEQ	2/15/2007	98105713	7/11/2013	1401248	ISSUED
UNITED STATES	14-126-003US	FOA	2/15/2007	11/707,546	8/22/2010	7,741,355	ISSUED
WIPO	14-126-003WO	CEQ	2/15/2007	PCT/US07/04053			NAT PHASE
UNITED STATES	14-126-003US CIP	CIP	11/19/2007	11/942,660	8/10/2010	7,772,266	ISSUED
SOUTH AFRICA	14-126-003ZA	DCA	9/5/2008	2008/07680	2/23/2011	2008/07680	ISSUED
CANADA	14-126-003CA CIP	DCA	11/17/2008	2,708,102			PENDING
EUROPEAN PATENT	14-126-003EP CIP	DCA	11/17/2008	08852382.4			PUBLISHED
WIPO	14-126-003WO CIP	CEQ	11/17/2008	PCT/US08/083810			NAT PHASE
HONG KONG	14-126-003HK	CEQ	5/5/2009	09104113.5			PENDING
UNITED STATES	14-126-003US CON	CON	6/8/2010	12/796,587	12/24/2013	8,614,243	ISSUED
UNITED STATES	14-126-003US CIP DIV	DIV	3/9/2010	12/853,202	12/31/2013	8,613,155 B2	ISSUED
JAPAN	14-126-003JP DIV	DIV	1/17/2013	2013-6063			PENDING

Confidential

PATENT
REEL: 036126 FRAME: 0280

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 4/16/2014

Page 7

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION							
UNITED STATES	14-126-002US PRV	NEW	8/22/2003	60/497,384			INACTIVE
UNITED STATES	14-126-002US	PCA	1/20/2004	10/922,413	1/29/2013	8,382,284	ISSUED
CANADA	14-126-002CA	DCA	8/20/2004	2,595,285	1/28/2014	2,595,285	ISSUED
EUROPEAN PATENT	14-126-002EP	DCA	8/20/2004	04781589.9			PENDING
JAPAN	14-126-002JP	DCA	8/20/2004	2006-524040	8/9/2013	5335191	ISSUED
WIPO	14-126-002WO	CEG	8/20/2004	PCT/US2004/026931			NAT PHASE
UNITED STATES	14-126-002US CON	CON	5/25/2011	13/115,893	3/5/2013	8,389,730 B2	ISSUED
UNITED STATES	14-126-002US CON2	CON	11/20/2012	13/632,151			PENDING

Confidential

PATENT
REEL: 036126 FRAME: 0281

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 9

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
---------	------------	------	-------	---------	--------	---------	--------

HCV Related Portfolio (Jointly owned with Schering and subject to Royalty Purchase by CPPIB)
Highlighted in Gray

NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS

CANADA	10-105-001DCAA	CEQ		2,473,032			PENDING
GERMANY	10-105-001DDE	DCA					MAILED
GERMANY	10-105-001DDE DIV	DCA					MAILED
UNITED STATES	10-105-P001D	NEW	7/21/2000	60/220,108			ABANDONED
ALBANIA	10-105-001DAL	DCA	7/19/2001	03731956.3	8/2/2010	1481000	ABANDONED
AUSTRIA	10-105-001DAT	DCA	7/19/2001	PCT/J052001/022678			PENDING
AUSTRIA	10-105-001DAT DIV	DCA	7/19/2001	03731956.3			ABANDONED
AUSTRALIA	10-105-001DAU	DCA	7/19/2001	2001276988	5/11/2007	2001276988	ISSUED
BELGIUM	10-105-001DBE	DCA	7/19/2001	01954764.5			PENDING
BELGIUM	10-105-001DBE DIV	DCA	7/19/2001	03731956.3			PENDING
BULGARIA	10-105-001DBG DIV	DCA	7/19/2001	03731956.3			ABANDONED
BRAZIL	10-105-001DBR	DCA	7/19/2001	PI0112540-0			PENDING
CANADA	10-105-001DCA	DCA	7/19/2001	2,410,662	9/18/2012	2,410,662	ISSUED
SWITZERLAND	10-105-001DCH	DCA	7/19/2001	01954764.5			PENDING
SWITZERLAND	10-105-001DCH DIV	DCA	7/19/2001	03731956.3			ABANDONED
COLOMBIA	10-105-001DCO	DCA	7/19/2001	03,003,340	11/29/2010	683	ISSUED
CYPRUS	10-105-001DCY	DCA	7/19/2001	01954764.5			PENDING
CYPRUS	10-105-001DCY DIV	DCA	7/19/2001	03731956.3			ABANDONED
CZECH REPUBLIC	10-105-001DCZ	DCA	7/19/2001	PV 2003-151			PUBLISHED
CZECH REPUBLIC	10-105-001DCZ DIV	DCA	7/19/2001	03731956.3			ABANDONED
DENMARK	10-105-001DDK	DCA	7/19/2001	01954764.5			PENDING
DENMARK	10-105-001DDK DIV	DCA	7/19/2001	03731956.3			ABANDONED
ECUADOR	10-105-001DEC	DCA	7/19/2001	SP03-4438 PCT			PENDING
ESTONIA	10-105-001DEE DIV	DCA	7/19/2001	03731956.3			ABANDONED
EUROPEAN PATENT	10-105-001DEP	DCA	7/19/2001	01954764.5	3/17/2010	1985870	ISSUED
EUROPEAN PATENT	10-105-001DEP DIV	DIV	7/19/2001	03731956.3	6/2/2010	1481000	ABANDONED
SPAIN	10-105-001DES	DCA	7/19/2001	01954764.5			PENDING
SPAIN	10-105-001DES DIV	DCA	7/19/2001	03731956.3			ABANDONED
FINLAND	10-105-001DFI	DCA	7/19/2001	01954764.5			PENDING
FINLAND	10-105-001DFI DIV	DCA	7/19/2001	03731956.3			ABANDONED
FRANCE	10-105-001DFR	DCA	7/19/2001	01954764.5			PENDING
FRANCE	10-105-001DFR DIV	DCA	7/19/2001	03731956.3			ABANDONED
UNITED KINGDOM	10-105-001DGB	DCA	7/19/2001	01954764.5			PENDING
UNITED KINGDOM	10-105-001DGB DIV	DCA	7/19/2001	03731956.3			ABANDONED
GREECE	10-105-001DGR	DCA	7/19/2001	01954764.5			PENDING
GREECE	10-105-001DGR DIV	DCA	7/19/2001	03731956.3			ABANDONED
HONG KONG	10-105-001DHK	CEQ	7/19/2001	04100762.2	12/10/2010	HK1058047	ISSUED
HUNGARY	10-105-001DHU	DCA	7/19/2001	P04 01730			PENDING
HUNGARY	10-105-001DHU DIV	DCA	7/19/2001	03731956.3			ABANDONED

Confidential

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 10

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
<i>NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS continued . . .</i>							
INDONESIA	10-105-001DID	DCA	7/19/2001	W002003 00127			PENDING
IRELAND	10-105-001DIE	DCA	7/19/2001	01954764.5			PENDING
IRELAND	10-105-001DIE DIV	DCA	7/19/2001	03731956.3			ABANDONED
ISRAEL	10-105-001DIL	DCA	7/19/2001	153,870			PENDING
INDIA	10-105-001DIN	DCA	7/19/2001	00089/CHENP/2003	5/16/2007	206685	ISSUED
ITALY	10-105-001DIT	DCA	7/19/2001	01954764.5			PENDING
ITALY	10-105-001DIT DIV	DCA	7/19/2001	03731956.3			ABANDONED
SOUTH KOREA	10-105-001DKR	DCA	7/19/2001	2003-7000794	6/19/2009	0904788	ISSUED
LIECHTENSTEIN	10-105-001DLI	DCA	7/19/2001	01954764.5			PENDING
LIECHTENSTEIN	10-105-001DLI DIV	DCA	7/19/2001	03731956.3			ABANDONED
LUXEMBOURG	10-105-001DLU	DCA	7/19/2001	01954764.5			PENDING
LUXEMBOURG	10-105-001DLU DIV	DCA	7/19/2001	03731956.3			ABANDONED
MONACO	10-105-001DMC	DCA	7/19/2001	01954764.5			PENDING
MONACO	10-105-001DMC DIV	DCA	7/19/2001	03731956.3			ABANDONED
MEXICO	10-105-001DMX	DCA	7/19/2001	PA/A/2005/00627	5/2/2009	256832	ISSUED
MALAYSIA	10-105-001DMY	CEQ	7/19/2001	PI200113456	8/23/2009	MY-139079A	ISSUED
MALAYSIA	10-105-001DMY DIV	DIV	7/19/2001	PI 2006-4797	4/15/2011	MY-143522A	ISSUED
NETHERLANDS	10-105-001DNL	DCA	7/19/2001	01954764.5			PENDING
NETHERLANDS	10-105-001DNL DIV	DCA	7/19/2001	03731956.3			ABANDONED
NORWAY	10-105-001DNO	DCA	7/19/2001	2003-0272			PENDING
NEW ZEALAND	10-105-001DNZ	CEQ	7/19/2001	523782	2/9/2006	523782	ISSUED
PERU	10-105-001DPE	CEQ	7/19/2001	732,2001			PENDING
PHILIPPINES	10-105-001DPH	CEQ	7/19/2001	1-2001-001848		1-2001-001848	ISSUED
POLAND	10-105-001DPL	DCA	7/19/2001	PCT/US01/22678			PENDING
PORTUGAL	10-105-001DPT	DCA	7/19/2001	01954764.5			PENDING
PORTUGAL	10-105-001DPT DIV	DCA	7/19/2001	03731956.3			ABANDONED
ROMANIA	10-105-001DRO	DCA	7/19/2001	03731956.3	6/2/2010	1481000	ABANDONED
RUSSIA	10-105-001DRU	DCA	7/19/2001	2003105217			PENDING
SWEDEN	10-105-001DSE	DCA	7/19/2001	01954764.5			PENDING
SWEDEN	10-105-001DSE DIV	DCA	7/19/2001	03731956.3			ABANDONED
SINGAPORE	10-105-001DSG	DCA	7/19/2001	200300058-5			PENDING
SLOVENIA	10-105-001DSI DIV	DCA	7/19/2001	03731956.3			ABANDONED
SLOVAK REPUBLIC	10-105-001DSK	DCA	7/19/2001	PP 0075-2003			PUBLISHED
SLOVAK REPUBLIC	10-105-001DSK DIV	DCA	7/19/2001	03731956.3			ABANDONED
THAILAND	10-105-001DTH	CEQ	7/19/2001	067080			PENDING
TURKEY	10-105-001DTR	DCA	7/19/2001	01954764.5	6/21/2010	TR 2010 03796 T4	ISSUED
TURKEY	10-105-001DTR DIV	DCA	7/19/2001	03731956.3			ABANDONED
UNITED STATES	10-105-001DUS	FCA	7/19/2001	09/908,955	9/14/2006	7,012,066	ISSUED
VENEZUELA	10-105-001DVE	CEQ	7/19/2001	2001-001546			PENDING
WIPO	10-105-001DWO	CEQ	7/19/2001	PCT/US01/22678		WO02/08244	NAT PHASE
SOUTH AFRICA	10-105-001DZA	DCA	7/19/2001	2002/10312			PENDING
ARGENTINA	10-105-001DAR	CEQ	7/20/2001	P010103450			PENDING
CHILE	10-105-001DCL	CEQ	7/20/2001	1724-2001			PENDING
TAIWAN	10-105-001DTW	CEQ	7/20/2001	090117804	5/11/2010	1324811	ISSUED
UNITED STATES	10-105-001DUSA	CIP	1/18/2002	10/052,366	7/17/2007	7,244,721	ISSUED
TAIWAN	10-105-001DTWA	CEQ	1/15/2003	092100868	12/21/2010	1334872	ISSUED

Confidential

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 11

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
<i>NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS continued . . .</i>							
AUSTRALIA	10-105-001DAUA	CEQ	1/16/2003	2003218064			ABANDONED
BRAZIL	10-105-001DBRA	CEQ	1/16/2003	PI0306931-1			PENDING
CHILE	10-105-001DCLA	CEQ	1/16/2003	2003-0067			PENDING
CHINA	10-105-001DCN	DCA	1/16/2003	038065933.9			PUBLISHED
JAPAN	10-105-001DJP	DCA	1/16/2003	2003-562142			PENDING
MALAYSIA	10-105-001DMYA	CEQ	1/16/2003	PI 20030137	1/15/2010	MY-140710-A	ABANDONED
NEW ZEALAND	10-105-001DNZA	CEQ	1/16/2003	PCT/US03/01430			PENDING
NEW ZEALAND	10-105-001DNZ DIV	DIV	1/16/2003	533662			ABANDONED
PERU	10-105-001DPEA	CEQ	1/16/2003	49.2003			PENDING
THAILAND	10-105-001DTHA	CEQ	1/16/2003	079485			PENDING
VENEZUELA	10-105-001DVEA	CEQ	1/16/2003	2003-000037			PENDING
WIPO	10-105-001DWOA	CEQ	1/16/2003	PCT/US03/01430		WO03/062265	NAT PHASE
ARGENTINA	10-105-001DARA	CEQ	1/17/2003	P 03 01 00131			PENDING
UNITED STATES	10-105-001DUS DIV	DIV	9/30/2005	11/241,858			ABANDONED
UNITED STATES	10-105-001DUSA DIV	DIV	3/6/2007	11/714,457	9/22/2009	7,592,316	ISSUED
UNITED STATES	10-105-001DUS DIV COCON		12/20/2010	12/973,020			ABANDONED
UNITED STATES	10-105-001DUS RI	RI	4/22/2011	13/068,159			PENDING

NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C

UNITED STATES	10-105-P001B	NEW	7/21/2000	60/220,109			ABANDONED
ARGENTINA	10-105-001BAR	CEQ	7/19/2001	P010103434			ABANDONED
CANADA	10-105-001BCA	DCA	7/19/2001	2,418,204			ABANDONED
EUROPEAN PATENT	10-105-001BEP	DCA	7/19/2001	01958046.2			ABANDONED
JAPAN	10-105-001BJP	DCA	7/19/2001	2002-514160			ABANDONED
TAIWAN	10-105-001BTW	CEQ	7/19/2001	50117894			ABANDONED
UNITED STATES	10-105-001BUS	FCA	7/19/2001	09/909,062	10/5/2004	6,860,434	ISSUED
WIPO	10-105-001BWO	CEQ	7/19/2001	PCT/US01/22826		WO01/06258	NAT PHASE
UNITED STATES	10-105-001BUS DIV	DIV	9/3/2004	10/934,141			ABANDONED

NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C

UNITED STATES	10-105-P001E	NEW	7/21/2000	60/220,101			ABANDONED
CANADA	10-105-001ECA	DCA	7/19/2001	2,418,193			ABANDONED
EUROPEAN PATENT	10-105-001EEP	DCA	7/19/2001	01955916.0			ABANDONED
JAPAN	10-105-001EJP	DCA	7/19/2001	2002-514155			ABANDONED
UNITED STATES	10-105-001EUS	FCA	7/19/2001	09/909,164			ABANDONED
WIPO	10-105-001EWO	CEQ	7/19/2001	PCT/US01/23189		WO02/08251	NAT PHASE

NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS

NEW ZEALAND	10-105-001CNZ DIV II	DIV					PROPOSED
NEW ZEALAND	10-105-001CNZ DIV II	CIP		571073			PENDING
UNITED STATES	10-105-P001C	NEW	7/21/2000	60/220,107			ABANDONED
AUSTRALIA	10-105-001CAU	DCA	7/19/2001	2001280637			ABANDONED
BRAZIL	10-105-001CBR	DCA	7/19/2001	PI0112666-6			ABANDONED
CANADA	10-105-001CCA	DCA	7/19/2001	2,410,682			ABANDONED
CHINA	10-105-001CCN	DCA	7/19/2001	01813921.3			ABANDONED

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 12

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
<i>NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS continued . . .</i>							
COLOMBIA	10-105-001CCO	DCA	7/19/2001	02115997			ABANDONED
CZECH REPUBLIC	10-105-001CCZ	DCA	7/19/2001	PV 2003-195			ABANDONED
EQUADOR	10-105-001CEC	DCA	7/19/2001	SP03-4439			ABANDONED
EUROPEAN PATENT	10-105-001CEP	DCA	7/19/2001	01959641.9			ABANDONED
HONG KONG	10-105-001CHK	CEQ	7/19/2001	03102910.0			ABANDONED
HUNGARY	10-105-001CHU	DCA	7/19/2001	P03 03958			ABANDONED
INDONESIA	10-105-001CID	DCA	7/19/2001	WO002003-09129			ABANDONED
ISRAEL	10-105-001CIL	DCA	7/19/2001	153,689			ABANDONED
INDIA	10-105-001CIN	DCA	7/19/2001	00688/CHENP/2003			ABANDONED
JAPAN	10-105-001CJP	DCA	7/19/2001	2002-514094	2/5/2010	4452441	ISSUED
MEXICO	10-105-001CMX	DCA	7/19/2001	PA/A/2003/00626			ABANDONED
MALAYSIA	10-105-001CMY	CEQ	7/19/2001	PI 20013417			PENDING
NORWAY	10-105-001CNO	DCA	7/19/2001	2003-0271			ABANDONED
NEW ZEALAND	10-105-001CNZ	DCA	7/19/2001	523751			ABANDONED
PERU	10-105-001CPE	CEQ	7/19/2001	733 2001			PENDING
PHILIPPINES	10-105-001CPH	CEQ	7/19/2001	1-2001-001847			PENDING
POLAND	10-105-001CPL	DCA	7/19/2001	PCT/US01/22313			ABANDONED
RUSSIA	10-105-001CRU	DCA	7/19/2001	2003 105 221			ABANDONED
SINGAPORE	10-105-001CSG	DCA	7/19/2001	200300032-0			ABANDONED
SLOVAK REPUBLIC	10-105-001CSK	DCA	7/19/2001	PP 0674-2003			ABANDONED
THAILAND	10-105-001CTH	CEQ	7/19/2001	067031			PENDING
UNITED STATES	10-105-001CUS	FCA	7/19/2001	09/009,012	1/30/2007	7,169,760	ISSUED
VENEZUELA	10-105-001CVE	CEQ	7/19/2001	2001-001547			PENDING
WIPO	10-105-001CWO	CEQ	7/19/2001	PCT/US01/22313		WO02/03197	NAT PHASE
SOUTH AFRICA	10-105-001CZA	DCA	7/19/2001	2002/10311			ABANDONED
ARGENTINA	10-105-001CAR	CEQ	7/20/2001	P010103451			PUBLISHED
CHILE	10-105-001CCL	CEQ	7/20/2001	1723-2001			PENDING
TAIWAN	10-105-001CTW	CEQ	7/20/2001	090117803			PENDING
NEW ZEALAND	10-105-001CNZ Div	DIV	1/16/2003	553706	8/12/2010	571073	ISSUED
SOUTH KOREA	10-105-001CKR	DCA	1/20/2003	2003-7000961			ABANDONED
UNITED STATES	10-105-001CUS Div	DIV	3/24/2005	11/059,132	9/29/2009	7,595,299	ISSUED

Confidential

PATENT
REEL: 036126 FRAME: 0285

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 13

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME							
WIPO	14-121-009WO	CEQ		PCT/US2014/054413			PENDING
UNITED STATES	14-121-009US PRV	FCA	9/5/2013	61/874,279			INACTIVE
UNITED STATES	14-121-009US PRV1	NEW	10/17/2013	61/892,373			INACTIVE
UNITED STATES	14-121-009US	FCA	9/5/2014	14/479,084			PENDING

PROMISCUOUS HER-2/NEU CD4 T CELL EPITOPES

UNITED STATES	14-121-007US PRV	NEW	8/11/2006	60/837,209			PENDING
UNITED STATES	14-121-007US	FCA	8/9/2007	11/836,645	7/5/2011	7,972,602	ISSUED
CANADA	14-121-007CA	CEQ	8/10/2007	2660178			PENDING
SWITZERLAND	14-121-007CH	DCA	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
GERMANY	14-121-007DE	CEQ	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
EUROPEAN PATENT	14-121-007EP	CEQ	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
SPAIN	14-121-007ES	CEQ	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
FRANCE	14-121-007FR	CEQ	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
UNITED KINGDOM	14-121-007GB	DCA	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
ITALY	14-121-007IT	DCA	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
JAPAN	14-121-007JP	CEQ	8/10/2007	2009-524009	2/1/2013	5189593	ISSUED
NETHERLANDS	14-121-007NL	DCA	8/10/2007	07813984.7	10/2/2013	2054430 B1	ISSUED
WIPO	14-121-007WO	CEQ	8/10/2007	PCT/US2007/075681			NAT PHASE
UNITED STATES	14-121-007US DIV	DIV	5/31/2011	13/149,408	9/11/2012	8,263,757 B2	ISSUED
EUROPEAN PATENT	14-121-007EP DIV	DIV	5/18/2012	12168585.3			PENDING
UNITED STATES	14-121-007US DIV2	DIV	8/16/2012	13/587,619			PENDING

PROMISCUOUS PAP CD4 T CELL EPITOPES

UNITED STATES	14-121-008US PRV	NEW	8/11/2006	60/837,053			PENDING
UNITED STATES	14-121-008US	FCA	8/9/2007	11/836,653	1/29/2013	8,361,479 B2	ISSUED
CANADA	14-121-008CA	CEQ	8/10/2007	PCT/US07/075704			PENDING
EUROPEAN PATENT	14-121-008EP	CEQ	8/10/2007	07840861.4			PENDING
JAPAN	14-121-008JP	CEQ	8/10/2007	2009-524012	2/1/2013	5189094	ISSUED
WIPO	14-121-008WO	CEQ	8/10/2007	PCT/US07/075704			NAT PHASE

COMPOSITION AND METHOD FOR PRODUCING AN IMMUNE RESPONSE AGAINST TUMOR-RELATED ANTIGENS

UNITED STATES	14-121-002US PRV	NEW	4/11/1997	60/043,301			INACTIVE
AUSTRALIA	14-121-002AU	DCA	4/10/1998	68979/98			ABANDONED
CANADA	14-121-002CA	DCA	4/10/1998	2,286,477			ABANDONED
EUROPEAN PATENT	14-121-002EP	DCA	4/10/1998	98914677.4			ABANDONED
HONG KONG	14-121-002HK	DCA	4/10/1998	00103995.9			ABANDONED
JAPAN	14-121-002JP	DCA	4/10/1998	10-544103			ABANDONED
UNITED STATES	14-121-002US	FCA	4/10/1998	09/402,845			ABANDONED
WIPO	14-121-002WO	CEQ	4/10/1998	PCT/US98/07232		WO98/46769	NAT PHASE
AUSTRALIA	14-121-002AU DIV	DIV	5/30/2002	44392/02			ABANDONED
UNITED STATES	14-121-002US CON	CON	2/4/2004	10/772,856	8/19/2008	7,414,108	ISSUED

Confidential

PATENT
REEL: 036126 FRAME: 0286

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 14

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
COMPOSITIONS AND METHODS EMPLOYING ALTERNATIVE READING FRAME POLYPEPTIDES FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE							
SWITZERLAND	14-127-001CH	DCA		04749357.2	10/15/2014	1601684	ISSUED
GERMANY	14-127-001DE	DCA			10/15/2014	1601684	ISSUED
EUROPEAN PATENT	14-127-001EP	DCA		04749357.2	10/15/2014	1601684	ISSUED
SPAIN	14-127-001ES	DCA		04749357.2	10/15/2014	1601684	ISSUED
FRANCE	14-127-001FR	DCA		04749357.2	10/15/2014	1601684	ISSUED
UNITED KINGDOM	14-127-001GB	DCA		04749357.2	10/15/2014	1601684	ISSUED
ITALY	14-127-001IT	DCA		04749357.2	10/15/2014	1601684	ISSUED
NETHERLANDS	14-127-001NL	DCA		04749357.2	10/15/2014	1601684	ISSUED
UNITED STATES	14-127-001US PRV	NEW	3/5/2003	60/453,131			INACTIVE
CANADA	14-127-001CA	DCA	3/5/2004	2,514,288			PENDING
UNITED STATES	14-127-001US	FCA	3/5/2004	10/794,514	10/6/2009	7,597,894	ISSUED
WIPO	14-127-001WO	CEQ	3/5/2004	PCT/US2004/006979			NAT PHASE
UNITED STATES	14-127-001US DIV	DIV	10/5/2009	12/573,685			PUBLISHED
EUROPEAN PATENT	14-127-001EP DIV	DIV	12/16/2011	11194012.8			PENDING

COMPOSITIONS AND METHODS FOR ENHANCEMENT OF MAJOR HISTO-COMPATIBILITY COMPLEX CLASS I RESTRICTED ANTIGEN PRESENTATION

UNITED STATES	14-121-004US PRV	NEW	12/14/1998	60/112,324			INACTIVE
AUSTRALIA	14-121-004AU	DCA	12/14/1999	20538/00	11/25/2004	775767	ISSUED
CANADA	14-121-004CA	DCA	12/14/1999	2,353,816	6/1/2010	2,353,816	ISSUED
GERMANY	14-121-004DE	DCA	12/14/1999	99964259.8	5/15/2013	1141007	ISSUED
EUROPEAN PATENT	14-121-004EP	DCA	12/14/1999	99964259.8	5/15/2013	1141007	ISSUED
FRANCE	14-121-004FR	DCA	12/14/1999	99964259.8	5/15/2013	1141007	ISSUED
UNITED KINGDOM	14-121-004GB	DCA	12/14/1999	99964259.8	5/15/2013	1141007	ISSUED
HONG KONG	14-121-004HK	DCA	12/14/1999	02100178.2			ABANDONED
JAPAN	14-121-004JP	DCA	12/14/1999	2000-588205			ABANDONED
NEW ZEALAND	14-121-004NZ	DCA	12/14/1999	512807	2/9/2004	512807	ISSUED
UNITED STATES	14-121-004US	FCA	12/14/1999	09/461,684	12/12/2006	7,148,324	ISSUED
WIPO	14-121-004WO	CEQ	12/14/1999	PCT/US99/29724	6/22/2000	WO 00/35949	NAT PHASE
UNITED STATES	14-121-004US CON	CON	6/16/2006	11/455,031	7/14/2009	7,560,104	ISSUED

BINDING PROTEINS SPECIFIC FOR HUMAN MATRIPTASE (Jointly-Owned with Amgen Fremont)

GERMANY	19-110-001DE	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
WIPO	19-110-001WO	CEQ	12/16/2005	PCT/US2005/045755			NAT PHASE
UNITED STATES	19-110-001US PRV	NEW	12/20/2004	60/637,859			INACTIVE
UNITED STATES	19-110-001US PRV1	OTH	8/8/2005	60/706,467			INACTIVE
AUSTRALIA	19-110-001AU	DCA	12/16/2005	2005319404	2/2/2012	2005319404	ISSUED
CANADA	19-110-001CA	DCA	12/16/2005	2,592,249	7/29/2014	2,592,249	ISSUED
SWITZERLAND	19-110-001CH	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
EUROPEAN PATENT	19-110-001EP	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
FRANCE	19-110-001FR	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
UNITED KINGDOM	19-110-001GB	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
ITALY	19-110-001IT	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
NETHERLANDS	19-110-001NL	DCA	12/16/2005	05854462.8	4/6/2011	1838737	ISSUED
TAIWAN	19-110-001TW	DCA	12/16/2005	094144958			ABANDONED
UNITED STATES	19-110-001US	FCA	12/16/2005	11/303,608	8/11/2009	7,572,444	ISSUED

MATRIPTASE INHIBITORS AND METHODS OF USE

UNITED STATES	10-110-P002AUS	NEW	12/23/2002	60/436,264			INACTIVE
UNITED STATES	10-110-002US	FCA	12/18/2003	10/740,946	3/28/2006	7,019,019	ISSUED
WIPO	10-110-002WO	CEQ	12/19/2003	PCT/US03/40927	7/15/2004	WO04/058688	ABANDONED

Confidential

PATENT
REEL: 036126 FRAME: 0287

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 15

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
GROWTH ARREST GENE COMPOSITIONS							
UNITED STATES	14-130-001US PRV	NEW	6/28/1996	60/021,874			INACTIVE
AUSTRALIA	14-130-001AU	DCA	6/27/1997	35101/97	9/7/2000	720324	ISSUED
CANADA	14-130-001CA	DCA	6/27/1997	2,259,337			ABANDONED
EUROPEAN PATENT	14-130-001EP	DCA	6/27/1997	97931484.6			ABANDONED
JAPAN	14-130-001JP	DCA	6/27/1997	10-504370			ABANDONED
NEW ZEALAND	14-130-001NZ	DCA	6/27/1997	333563	12/7/2000	333563	ISSUED
UNITED STATES	14-130-001US	FCA	6/27/1997	08/883,070	12/7/1999	5,998,599	ISSUED
WIPO	14-130-001WO	CEQ	6/27/1997	PCT/US97/11341		WO98/00544	NAT PHASE

METHODS FOR INDUCING A NATURAL KILLER (NK) CELL-MEDIATED IMMUNE RESPONSE AND FOR INCREASING NK CELL ACTIVITY

UNITED STATES	14-123-008US PRV	NEW	3/22/2007	60/896,461			INACTIVE
CANADA	14-123-008CA	DCA	3/21/2008	2,682,661			PUBLISHED
EUROPEAN PATENT	14-123-008EP	DCA	3/21/2008	EP08727066.6			PUBLISHED
UNITED STATES	14-123-008US	FCA	3/21/2008	12/077,823	4/10/2012	8,153,120	ISSUED
WIPO	14-123-008WO	CEQ	3/21/2008	PCT/US2008/003755			NAT PHASE
UNITED STATES	14-123-008US DIV	DIV	4/10/2012	13/443,703			PENDING

METHODS FOR ENRICHING BREAST TUMOR CELLS

UNITED STATES	14-122-004US	NEW	8/31/1994	08/299,465	7/15/1997	5,648,223	ISSUED
---------------	--------------	-----	-----------	------------	-----------	-----------	--------

METHODS FOR ENRICHING FETAL CELLS FROM MATERNAL BODY FLUIDS

UNITED STATES	14-122-002US	NEW	8/31/1994	08/299,468	7/8/1997	5,646,004	ISSUED
---------------	--------------	-----	-----------	------------	----------	-----------	--------

METHODS FOR ENRICHING SPECIFIC CELL-TYPES BY DENSITY GRADIENT CENTRIFUGATION

UNITED STATES	14-122-003US	NEW	8/31/1994	08/299,467	11/24/1998	5,840,502	ISSUED
---------------	--------------	-----	-----------	------------	------------	-----------	--------

INHIBITORS OF SERINE PROTEASE ACTIVITY OF MATRIPTASE (MTSP1)

UNITED STATES	10-110-001US	NEW	9/8/2000	09/657,986	9/28/2004	6,797,504	ISSUED
AUSTRALIA	10-110-001AU	DCA	9/7/2001	2001288922			ABANDONED
CANADA	10-110-001CA	DCA	9/7/2001	2,422,157			ABANDONED
EUROPEAN PATENT	10-110-001EP	DCA	9/7/2001	01968692.2			ABANDONED
JAPAN	10-110-001JP	DCA	9/7/2001	2002-525098			ABANDONED
SOUTH KOREA	10-110-001KR	DCA	9/7/2001	2003-7003459			ABANDONED
WIPO	10-110-001WO	CEQ	9/7/2001	PCT/US01/28137		WO02/20475	NAT PHASE
UNITED STATES	10-110-001USA	CIP	3/5/2002	10/092,004	1/2/2007	7,157,596	ISSUED

INHIBITORS OF UROKINASE

UNITED STATES	10-107-001US	CIP	7/24/1998	09/121,921	6/10/2003	6,576,613	ABANDONED
AUSTRALIA	10-107-001AUA	DCA	7/22/1999	50058/99	8/26/2004	772024	ABANDONED
CANADA	10-107-001CAA	DCA	7/22/1999	2,338,524	1/22/2013	2,338,524	ABANDONED
CHINA	10-107-001CNA	DCA	7/22/1999	99810002.1			ABANDONED
CZECH REPUBLIC	10-107-001CZA	DCA	7/22/1999	PV 2001-276			ABANDONED
EUROPEAN PATENT	10-107-001EPA	DCA	7/22/1999	99934173.8			ABANDONED
ISRAEL	10-107-001ILA	DCA	7/22/1999	140939			ABANDONED
JAPAN	10-107-001JPA	DCA	7/22/1999	2000-561201			ABANDONED
SOUTH KOREA	10-107-001KRA	DCA	7/22/1999	10-2001-7000985			ABANDONED
NEW ZEALAND	10-107-001NZA	DCA	7/22/1999	509400	3/29/2004	509400	ISSUED
POLAND	10-107-001PLA	DCA	7/22/1999	P345960			ABANDONED
UNITED STATES	10-107-001USA	CIP	7/22/1999	09/359,929	8/13/2002	6,432,922	ABANDONED
WIPO	10-107-001WOA	CEQ	7/22/1999	PCT/US99/16577		WO00/05245	NAT PHASE

Confidential

PATENT
REEL: 036126 FRAME: 0288

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 16

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
ASP-PRO-ARG a-KETO-AMIDE ENZYME INHIBITORS							
UNITED STATES	10-103-005US	NEW	10/16/1992	07/962,301	12/6/1994	5,371,072	EXPIRED
AUSTRALIA	10-103-005AUB	DCA	10/18/1993	54081/94	9/11/1997	678189	ABANDONED
CANADA	10-103-005CAB	DCA	10/18/1993	2,146,446			ABANDONED
EUROPEAN PATENT	10-103-005EPB	CEQ	10/18/1993	93924369.7	3/24/1999	EP0664786	EXPIRED
JAPAN	10-103-005JPB	DCA	10/18/1993	510359/1994			ABANDONED
NETHERLANDS	10-103-005NLB	DCA	10/18/1993	93924369.7	3/24/1999	EP0664786	ABANDONED
UNITED STATES	10-103-005USA	CIP	10/18/1993	08/139,300	1/28/1997	5,597,804	EXPIRED
WIPO	10-103-005WOB	DCA	10/18/1993	PCT/US93/10015	4/28/1994	WO94/09841	NAT PHASE
UNITED STATES	10-103-005USB	CON	6/5/1995	08/462,899	2/9/1999	5,869,454	ISSUED
SELECTIVE APOPTOSIS OF NEOPLASTIC CELLS BY AN HLA-DR SPECIFIC MONOCLONAL ANTIBODY							
UNITED STATES	14-125-001US PRV	NEW	8/28/1998	60/098,292			INACTIVE
EUROPEAN PATENT	14-125-001EP	DCA	8/26/1999	99942522.6			ABANDONED
UNITED STATES	14-125-001US	FCA	8/26/1999	09/383,663			ABANDONED
WIPO	14-125-001WO	CEQ	8/26/1999	PCT/US99/19628		WO 00/122560	ABANDONED
UNITED STATES	14-125-001US DIV	DIV	8/13/2001	09/929,209	7/9/2002	6,416,958	ISSUED
HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS							
UNITED STATES	14-125-002US PRV	NEW	12/15/2003	60/608,944			INACTIVE
CANADA	14-125-002CA	DCA	12/15/2004	2,550,155			PUBLISHED
EUROPEAN PATENT	14-125-002EP	DCA	12/15/2004	04814490.1-2402			ABANDONED
JAPAN	14-125-002JP	DCA	12/15/2004	2006-544134			ABANDONED
UNITED STATES	14-125-002US	FCA	12/15/2004	11/013,537	1/15/2013	8,354,507	ISSUED
WIPO	14-125-002WO	CEQ	12/15/2004	PCT/US2004/042312			NAT PHASE

Confidential

PATENT
REEL: 036126 FRAME: 0289

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 17

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
---------	------------	------	-------	---------	--------	---------	--------

3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING ANARGININE MIMIC AS ENZYME INHIBITORS

UNITED STATES	10-103-001US	NEW	6/17/1994	08/261,498	2/3/1998	5,714,499	ISSUED
UNITED STATES	10-103-001USA	CIP	6/7/1995	08/482,117	8/3/1999	5,932,733	ISSUED
UNITED STATES	10-103-001USB	CIP	6/7/1995	08/484,260			ABANDONED
CANADA	10-103-001CA	DCA	6/19/1995	2192211			ABANDONED
EUROPEAN PATENT	10-103-001EP	DCA	6/19/1995	95924623.2	1/27/1999	EP0765339	NAT PHASE
JAPAN	10-103-001JP	DCA	6/19/1995	8-502570			ABANDONED
NETHERLANDS	10-103-001NL	DCA	6/19/1995	95924623.2	1/27/1999	EP0765339	ABANDONED
WIPO	10-103-001WO	DCA	6/19/1995	PCT/US95/07832		WO95/35313	NAT PHASE

3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES AS ENZYME INHIBITORS

UNITED STATES	10-103-002US	NEW	6/17/1994	08/261,378			ABANDONED
UNITED STATES	10-103-002USA	CON	6/6/1995	08/480,475			ABANDONED
UNITED STATES	10-103-002USC	CIP	6/7/1995	08/484,720	12/30/1997	5,703,208	ISSUED
UNITED STATES	10-103-002USB	CIP	6/7/1995	08/487,007			ABANDONED
AUSTRALIA	10-103-002AUC	DCA	6/19/1995	28630/95	4/29/1999	700808	ABANDONED
BRAZIL	10-103-002BRC	DCA	6/19/1995	PI9508048-1			ABANDONED
CANADA	10-103-002CAC	DCA	6/19/1995	2192210			ABANDONED
CHINA	10-103-002CNC	DCA	6/19/1995	95193661.1			ABANDONED
EUROPEAN PATENT	10-103-002EPC	CEQ	6/19/1995	95923922.9			ABANDONED
JAPAN	10-103-002JPC	DCA	6/19/1995	8-502499			ABANDONED
SOUTH KOREA	10-103-002KRC	DCA	6/19/1995	707245/1996			ABANDONED
MEXICO	10-103-002MXC	DCA	6/19/1995	966566	12/5/2000	199952	ABANDONED
NORWAY	10-103-002NOC	DCA	6/19/1995	965353			ABANDONED
NEW ZEALAND	10-103-002NZC	DCA	6/19/1995	288940	5/11/1999	288940	ABANDONED
WIPO	10-103-002WOC	DCA	6/19/1995	PCT/US95/07661	12/28/1995	WO95/35311	NAT PHASE

3-AMINO-2-OXO-AZEPINE DERIVATIVES AS ENZYME INHIBITORS

UNITED STATES	10-103-003US	NEW	12/13/1994	08/356,831			ABANDONED
UNITED STATES	10-103-003USA	CON	10/14/1997	08/950,270	3/7/2000	6,034,215	ISSUED

Confidential

PATENT
REEL: 036126 FRAME: 0290

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 18

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
BLOOD COAGULATION PROTEIN ANTAGONISTS							
UNITED STATES	10-111-001US	NEW	10/22/1990	07/601,454			ABANDONED
UNITED STATES	10-111-001USA	CIP	9/13/1991	07/759,443	4/9/1996	5,506,134	EXPIRED
AUSTRALIA	10-111-001AU	DCA	10/17/1991	90298/91	3/14/1995	654311	ABANDONED
CANADA	10-111-001CA	DCA	10/17/1991	2,094,372			ABANDONED
GERMANY	10-111-001DE	DCA	10/17/1991	EP0554383	8/2/2000	69132352.6	ABANDONED
EUROPEAN PATENT	10-111-001EP	CEQ	10/17/1991	91920567.4	8/2/2000	EP0554383	NAT PHASE
SPAIN	10-111-001ES	DCA	10/17/1991	91920567.4	8/2/2000	EP0554383	ABANDONED
FRANCE	10-111-001FR	DCA	10/17/1991	91920567.4	8/2/2000	EP0554383	ABANDONED
UNITED KINGDOM	10-111-001GB	DCA	10/17/1991	91920567.4	8/2/2000	EP0554383	ABANDONED
ITALY	10-111-001IT	DCA	10/17/1991	91920567.4	8/2/2000	EP0554383	ABANDONED
JAPAN	10-111-001JP	DCA	10/17/1991	518610/1991	8/1/1997	2680192	ABANDONED
LUXEMBOURG	10-111-001LU	DCA	10/17/1991	91920567.4	8/2/2000	EP0554383	ABANDONED
NETHERLANDS	10-111-001NL	DCA	10/17/1991	91920567.4	8/2/2000	EP0554383	ABANDONED
WIPO	10-111-001WO	DCA	10/17/1991	PCT/US91/07811		WO92/06711	NAT PHASE
UNITED STATES	10-111-001USAA	R62	12/6/1993	08/163,576			ABANDONED
UNITED STATES	10-111-001USB	CON	5/30/1995	08/453,047	12/1/1998	5,843,442	ISSUED
UNITED STATES	10-111-004USA	R62	1/15/1998	09/008,121	4/24/2001	6,221,659	EXPIRED

BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa

UNITED STATES	10-104-001US	NEW	7/13/1992	07/913,232			ABANDONED
UNITED STATES	10-104-001USA	CIP	11/3/1992	07/952,801			ABANDONED
CANADA	10-104-001CA	DCA	7/1/1993	2139945			ABANDONED
EUROPEAN PATENT	10-104-001EP	CEQ	7/1/1993	93917108.8			ABANDONED
JAPAN	10-104-001JP	DCA	7/1/1993	503560/1994			ABANDONED
UNITED STATES	10-104-001USAA	CIP	7/1/1993	08/086,328	9/15/1998	5,807,980	ISSUED
UNITED STATES	10-104-001USB	CIP	7/1/1993	08/086,630	5/5/1998	5,747,449	ISSUED
WIPO	10-104-001WO	DCA	7/1/1993	PCT/US93/06530		WO94/01461	NAT PHASE
UNITED STATES	10-104-001USAB	CON	6/1/1995	08/456,754			ABANDONED

METHIONINE SULFONE AND S-SUBSTITUTED CYSTEINE SULFONE DERIVATIVES AS ENZYME INHIBITORS

UNITED STATES	10-104-006US	NEW	4/18/1994	08/229,298	7/7/1998	5,776,927	ISSUED
UNITED STATES	10-104-006USA	CIP	4/28/1994	08/234,811	10/28/1997	5,681,844	EXPIRED
CANADA	10-104-006CAA	DCA	4/18/1995	2188162			ABANDONED
EUROPEAN PATENT	10-104-006EP	CEQ	4/18/1995	95917624.9	8/30/2000	EP0765340	ABANDONED
UNITED KINGDOM	10-104-006GB	DCA	4/18/1995	95917624.9	8/30/2000	EP0765340	ABANDONED
JAPAN	10-104-006JPA	DCA	4/18/1995	527181/1995			ABANDONED
NETHERLANDS	10-104-006NL	DCA	4/18/1995	95917624.9	8/30/2000	EP0765340	ABANDONED
UNITED STATES	10-104-006USB	CIP	4/18/1995	08/423,584	8/19/1997	5,658,939	EXPIRED
WIPO	10-104-006WOA	CEQ	4/18/1995	PCT/US95/04954		WO95/28420	NAT PHASE
UNITED STATES	10-104-006USC	CON	6/6/1995	08/485,826	7/8/1997	5,646,165	EXPIRED
UNITED STATES	10-104-006USD	CON	6/6/1995	08/473,647	6/23/1998	5,770,600	ISSUED
UNITED STATES	10-104-006USE	CON	2/10/1998	09/021,663			ABANDONED

Confidential

PATENT
REEL: 036126 FRAME: 0291

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 19

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTI-COAGULANT PROTEINS (Subject to out-license to ARCA Biopharma formerly known as Nuvelo)							
UNITED STATES	10-101-001USO CON	CON		11/454,308			ABANDONED
UNITED STATES	10-101-001US	NEW	10/18/1994	08/326,110	8/31/1999	5,945,275	ISSUED
UNITED STATES	10-101-001USB	CIP	6/5/1995	08/465,380	1/26/1999	5,863,894	ISSUED
UNITED STATES	10-101-001USE	CIP	6/5/1995	08/486,397	2/2/1999	5,866,542	ISSUED
UNITED STATES	10-101-001USF	CIP	6/5/1995	08/486,399	2/2/1999	5,866,543	ISSUED
UNITED STATES	10-101-001USD	CIP	6/5/1995	08/461,965	2/16/1999	5,872,098	ISSUED
UNITED STATES	10-101-001USC	CON	6/6/1995	08/480,478	1/26/1999	5,864,009	ISSUED
AUSTRIA	10-101-001AT	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
AUSTRALIA	10-101-001AUA	DCA	10/17/1995	41307/96	1/27/2000	711405	ABANDONED
BELGIUM	10-101-001BEA	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
CANADA	10-101-001CAA	DCA	10/17/1995	2,202,351			ABANDONED
SWITZERLAND	10-101-001CH	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
GERMANY	10-101-001DE	DCA	10/17/1995	69535317	11/29/2006	69535317	ABANDONED
EUROPEAN PATENT	10-101-001EPA	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
SPAIN	10-101-001ES	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
FRANCE	10-101-001FR	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
UNITED KINGDOM	10-101-001GBA	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
GREECE	10-101-001GR	DCA	10/17/1995	3061013	11/29/2006	0788546	ABANDONED
HUNGARY	10-101-001HUA	DCA	10/17/1995	P9800027	5/24/2006	225126	ABANDONED
IRELAND	10-101-001IEA	CEQ	10/17/1995	95939520.3		0788546	ABANDONED
ITALY	10-101-001ITA	CEQ	10/17/1995	95939520.3		0788546	ABANDONED
JAPAN	10-101-001JPA	DCA	10/17/1995	8-513399	6/2/2006	3811186	ABANDONED
SOUTH KOREA	10-101-001KRA	DCA	10/17/1995	10-1997-0702517	11/23/2005	0532190	ABANDONED
MONACO	10-101-001MC	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
NETHERLANDS	10-101-001NL	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
NEW ZEALAND	10-101-001NZAA	DIV	10/17/1995	509891			ABANDONED
NEW ZEALAND	10-101-001NZA	DCA	10/17/1995	296648			PUBLISHED
POLAND	10-101-001PLA	DCA	10/17/1995	P319782	10/17/1995	183855	ABANDONED
PORTUGAL	10-101-001PT	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
SWEDEN	10-101-001SE	DCA	10/17/1995	95939520.3	11/29/2006	0788546	ABANDONED
WIPO	10-101-001WOA	DCA	10/17/1995	PCT/US95/13231		WO96/12021	NAT PHASE
UNITED STATES	10-101-001USG	CIP	4/19/1996	08/634,641	9/21/1999	5,955,294	EXPIRED
UNITED STATES	10-101-001USAA	DCA	11/24/1997	08/809,455	7/18/2000	6,090,916	ABANDONED
UNITED STATES	10-101-001USN	CON	2/12/1999	09/249,471	3/21/2000	6,040,441	EXPIRED
UNITED STATES	10-101-001USK	CON	2/12/1999	09/249,473	3/18/2003	6,534,629	ISSUED
UNITED STATES	10-101-001USH	CON	2/12/1999	09/249,448	9/19/2000	6,121,435	EXPIRED
UNITED STATES	10-101-001USL	CON	2/12/1999	09/249,451	7/11/2000	6,087,487	EXPIRED
UNITED STATES	10-101-001USI	CON	2/12/1999	09/249,461	8/1/2000	6,096,877	EXPIRED
UNITED STATES	10-101-001USJ	CON	2/12/1999	09/249,472	4/4/2000	6,046,318	EXPIRED
UNITED STATES	10-101-001USAB	CON	2/4/2000	09/498,272			ABANDONED
UNITED STATES	10-101-001USM	CON	2/4/2000	09/498,556	3/29/2005	6,872,808	EXPIRED
NEW ZEALAND	10-101-001NZAB	DIV	12/17/2004	537271	1/11/2007	537271	ABANDONED
UNITED STATES	10-101-001USO	CON	3/29/2005	11/092,336			ABANDONED
JAPAN	10-101-001JPA DIV	DIV	10/19/2005	2005-304883	3/28/2008	4101833	ABANDONED
NEW ZEALAND	10-101-001NZAB DIV	DIV	6/19/2006	547989			ABANDONED
EUROPEAN PATENT	10-101-001EPA DIV	DIV	11/6/2006	06123554.5			ABANDONED
JAPAN	10-101-001JPA DIV2	DIV	12/28/2006	2006-356647			ABANDONED
DENMARK	10-101-001DK	DCA	2/28/2007	95939520.3		0788546	ABANDONED
HONG KONG	10-101-001HK	DCA	9/14/2007	07110084.9			ABANDONED
UNITED STATES	10-101-001USO CON DIDIV		10/27/2008	12/290,059			ABANDONED

Confidential

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 20

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
---------	------------	------	-------	---------	--------	---------	--------

METHOD OF TREATMENT OF HEMORRHAGIC DISEASE USING A FACTOR VII/A TISSUE FACTOR (Subject to out-license to ARCA Biopharma formerly known as Nuvelo)

UNITED STATES	10-101-002US	NEW	5/6/2003	10/431,629	11/7/2006	7,132,398	ISSUED
WIPO	10-101-002WO	CEQ	5/5/2004	PCT/US04/13942			NAT PHASE
SOUTH AFRICA	10-101-002ZA	DCA	5/5/2004	2005/09858			ABANDONED
UNITED STATES	10-101-002US CON	CON	9/12/2006	11/520,079	2/12/2008	7,329,640	ISSUED

PROCESS FOR MANUFACTURING OF NEMATODE-EXTRACTED ANTICOAGULANT PROTEIN (NAP) (Subject to out-license to ARCA Biopharma formerly known as Nuvelo)

UNITED STATES	10-101-003US	NEW	5/15/2003	10/440,475			ABANDONED
AUSTRALIA	10-101-003AU	DCA	5/14/2004	2004240623	10/28/2010	2004240623	ABANDONED
CANADA	10-101-003CA	DCA	5/14/2004	2,525,831			ABANDONED
CHINA	10-101-003CN	DCA	5/14/2004	200480020327.X		200480020327.X	ABANDONED
EUROPEAN PATENT	10-101-003EP	CEQ	5/14/2004	04752181.0			ABANDONED
INDIA	10-101-003IN	DCA	5/14/2004	5456/DELNP/2005			ABANDONED
JAPAN	10-101-003JP	DCA	5/14/2004	2006-533059			ABANDONED
MEXICO	10-101-003MX	DCA	5/14/2004	PA/A/2005/012298	3/27/2009	265473	ABANDONED
RUSSIA	10-101-003RU	CEQ	5/14/2004	2005139130	5/20/2009	2355770	ABANDONED
WIPO	10-101-003WO	CEQ	5/14/2004	PCT/US04/15100			NAT PHASE
SOUTH AFRICA	10-101-003ZA	DCA	5/14/2004	2005/10150		2005/10150	ABANDONED
UNITED STATES	10-101-003US CON	CON	12/20/2005	11/313,303	10/9/2007	7,279,309	ISSUED
UNITED STATES	10-101-003 US CON2	CON	6/14/2007	11/818,324			PUBLISHED

NON COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION HAVING A PYRIDONE GROUP

UNITED STATES	10-107-P004AUS	NEW	12/4/2001	60/337,100			ABANDONED
UNITED STATES	10-107-004AUS	CIP	12/4/2002	10/309,781	10/28/2007	7,262,211	ISSUED
WIPO	10-107-004AWO	CEQ	12/4/2002	PCT/US02/38788			ABANDONED

Confidential

PATENT
REEL: 036126 FRAME: 0293

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 21

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
NOVEL INHIBITORS OF FACTOR Xa							
UNITED STATES	10-104-004US	NEW	12/15/1992	07/991,204			ABANDONED
CANADA	10-104-004CAA	DCA	12/15/1993	2,151,044			ABANDONED
EUROPEAN PATENT	10-104-004EPA	CEQ	12/15/1993	94904466.3	3/17/1999	EP0675899	ABANDONED
JAPAN	10-104-004JPA	DCA	12/15/1993	514525/1994			ABANDONED
NETHERLANDS	10-104-004NL	DCA	12/15/1993	94904466.3	3/17/1999	EP0675899	ABANDONED
UNITED STATES	10-104-004USA	CIP	12/15/1993	08/168,964	3/16/1999	5,883,077	ISSUED
WIPO	10-104-004WOA	DCA	12/15/1993	PCT/US93/12255		WO94/13693	NAT PHASE
UNITED STATES	10-104-004USB	CON	6/5/1995	08/465,115	4/14/1998	5,739,112	ISSUED
NOVEL NEUTROPHIL INHIBITORS							
CANADA	10-102-002CA	DCA	12/23/1993	2152599			ABANDONED
EUROPEAN PATENT	10-102-002EP	CEQ	12/23/1993	94907114.6			ABANDONED
JAPAN	10-102-002JP	DCA	12/23/1993	515483/1994			ABANDONED
NEW ZEALAND	10-102-002NZ	DCA	12/23/1993	261662	8/19/1997	261662	ABANDONED
UNITED STATES	10-102-002USC	CIP	12/23/1993	08/173,510	5/5/1998	5,747,296	ISSUED
WIPO	10-102-002WO	DCA	12/23/1993	PCT/US93/12626		WO94/14973	NAT PHASE
UNITED STATES	10-102-002USE	CON	5/26/1995	08/450,492			ABANDONED
NEW ZEALAND	10-102-002NZA	DIV	2/14/1997	314241	5/18/1999	314241	ABANDONED
NOVEL NEUTROPHIL INHIBITORS							
UNITED STATES	10-102-001USB	CIP	5/11/1993	08/060,433	6/29/2004	6,756,211	EXPIRED
UNITED STATES	10-102-002US	CIP	11/10/1993	08/151,064	11/8/2005	6,962,795	ISSUED
UNITED STATES	10-102-001USC	R62	5/24/1994	08/249,041	1/13/1998	5,708,141	ISSUED
UNITED STATES	10-102-002USD	DIV	5/26/1995	08/450,497	7/6/1999	5,919,900	ISSUED
UNITED STATES	10-102-002USF	DIV	5/26/1995	08/450,482	11/16/2004	6,818,616	ISSUED
UNITED STATES	10-102-002USA	CON	6/2/1995	08/458,216			ABANDONED
UNITED STATES	10-102-002USB	CON	6/2/1995	08/458,218	8/4/1998	5,789,178	ISSUED
NOVEL NON-COVALENT THROMBIN INHIBITORS							
UNITED STATES	10-103-023US	NEW	7/13/2001	09/905,644	8/17/2004	6,777,431	ISSUED
N-SUBSTITUTED GLYCINE DERIVATIVES AS ENZYME INHIBITORS							
UNITED STATES	10-104-003US	NEW	12/21/1994	08/361,794	12/9/1997	5,696,231	ISSUED
UNITED STATES	10-104-003USA	CIP	6/7/1995	08/484,509	2/15/2000	6,025,472	ISSUED

Confidential

PATENT
REEL: 036126 FRAME: 0294

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 22

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 10, THE ENCODED PROTEINS AND METHODS BASED THEREON							
UNITED STATES	10-109-P010A	NEW	5/14/2001	60/291,001			ABANDONED
AUSTRALIA	10-109-010AAU	DCA	5/14/2002	2002305595			ABANDONED
CANADA	10-109-010ACA	DCA	5/14/2002	2,447,050			ABANDONED
EUROPEAN PATENT	10-109-010AEP	DCA	5/14/2002	02734425.8			ABANDONED
JAPAN	10-109-010AJP	DCA	5/14/2002	2002-589707			ABANDONED
SOUTH KOREA	10-109-010AKR	DCA	5/14/2002	10-2003-7014855			ABANDONED
NEW ZEALAND	10-109-010ANZ	DCA	5/14/2002	528931			ABANDONED
UNITED STATES	10-109-010AUS	FCA	5/14/2002	10/147,211	9/26/2006	7,112,430	ISSUED
WIPO	10-109-010AWO	CEQ	5/14/2002	PCT/US02/15332			NAT PHASE

NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 14, ENCODED PROTEINS AND METHODS BASED THEREON (MTSP14)

UNITED STATES	10-109-P008A	NEW	3/22/2001	60/278,166			ABANDONED
AUSTRALIA	10-109-008AAU	DCA	3/20/2002	2002254357			ABANDONED
CANADA	10-109-008ACA	DCA	3/20/2002	2,441,378			ABANDONED
EUROPEAN PATENT	10-109-008AEP	DCA	3/20/2002	02723586.0			ABANDONED
JAPAN	10-109-008AJP	DCA	3/20/2002	2002575305			ABANDONED
SOUTH KOREA	10-109-008AKR	DCA	3/20/2002	10-2003-7012261			ABANDONED
NEW ZEALAND	10-109-008ANZ	DCA	3/20/2002	527970			ABANDONED
UNITED STATES	10-109-008AUS	FCA	3/20/2002	10/104,271	2/6/2007	7,172,892	ISSUED
WIPO	10-109-008AWO	CEQ	3/20/2002	PCT/US02/09039			NAT PHASE

NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 9, THE ENCODED PROTEINS AND METHODS BASED THEREON

UNITED STATES	10-109-P009A	NEW	3/27/2001	60/279,228			ABANDONED
AUSTRALIA	10-109-009AAU	DCA	3/27/2002	2002252531			ABANDONED
CANADA	10-109-009ACA	DCA	3/27/2002	2,442,089			ABANDONED
EUROPEAN PATENT	10-109-009AEP	DCA	3/27/2002	02721608.4			ABANDONED
JAPAN	10-109-009AJP	DCA	3/27/2002	2002-575309			ABANDONED
SOUTH KOREA	10-109-009AKR	DCA	3/27/2002	10-2003-7012622			ABANDONED
NEW ZEALAND	10-109-009ANZ	DCA	3/27/2002	527971			ABANDONED
UNITED STATES	10-109-009AUS	FCA	3/27/2002	10/112,221	9/12/2006	7,105,333	ISSUED
WIPO	10-109-009AWO	CEQ	3/27/2002	PCT/US02/09611			NAT PHASE

NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, THE ENCODED PROTEINS AND METHODS BASED THEREOF (MTSP 1, 3, 4 & 6)

GERMANY	10-109-002ADE	DCA				EP1252300	ISSUED
UNITED STATES	10-109-P002B	OTH	2/18/2000	60/183,542			ABANDONED
UNITED STATES	10-109-P002CUS	OTH	6/22/2000	60/213,124			ABANDONED
UNITED STATES	10-109-P002DUS	OTH	7/26/2000	60/220,970			ABANDONED
UNITED STATES	10-109-P002E	OTH	9/22/2000	60/234,840			ABANDONED
AUSTRALIA	10-109-002AAU	DCA	2/2/2001	2001233262			ABANDONED
CANADA	10-109-002ACA	DCA	2/2/2001	2,396,774			ABANDONED
EUROPEAN PATENT	10-109-002AEP	DCA	2/2/2001	01905377.6	1/19/2011	EP1252300	ISSUED
FRANCE	10-109-002AFR	DCA	2/2/2001	01905377.6	1/19/2011	EP1252300	ISSUED
UNITED KINGDOM	10-109-002AGB	DCA	2/2/2001	01905377.6	1/19/2011	EP1252300	ISSUED

Confidential

PATENT
REEL: 036126 FRAME: 0295

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 23

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
<i>NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, (MTSP 1, 3, 4 & 6) continued...</i>							
IRELAND	10-109-002AIE	DCA	2/2/2001	01905377.6	1/19/2011	EP1252300	ISSUED
ISRAEL	10-109-002AIL	DCA	2/2/2001	150168			ABANDONED
JAPAN	10-109-002AJP	DCA	2/2/2001	2001-558009			ABANDONED
SOUTH KOREA	10-109-002AKR	DCA	2/2/2001	10-2002-7009973			ABANDONED
NEW ZEALAND	10-109-002ANZ	DCA	2/2/2001	519635			ABANDONED
RUSSIA	10-109-002ARU	DCA	2/2/2001	2002120920			ABANDONED
UNITED STATES	10-109-002AUS	CIP	2/2/2001	09/776,191	4/20/2010	7,700,341	ISSUED
WIPO	10-109-002AWO	CEQ	2/2/2001	PCT/US01/03471		WO01/57194	NAT PHASE
SOUTH AFRICA	10-109-002AZA	DCA	2/2/2001	2002/5678	12/31/2003	2002/5678	ISSUED
NEW ZEALAND	10-109-002ANZ DIV	DIV	11/15/2005	543579			ABANDONED
UNITED STATES	10-109-002AUS DIV	DIV	10/30/2009	12/590,011	2/15/2011	7,888,092	ISSUED
UNITED STATES	10-109-002AUS DIV2	DIV	11/12/2010	12/927,372			PUBLISHED

NUCLEIC ACIDS MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE, THE ENCODING PROTEINS AND METHODS BASED THEREON (MTSP7)

UNITED STATES	10-109-P007A	NEW	3/13/2001	60/275,592			ABANDONED
UNITED STATES	10-109-007AUS	FCA	3/13/2002	10/099,700	10/24/2006	7,125,703	ISSUED
WIPO	10-109-007AWO	CEQ	3/13/2002	PCT/US02/07903			ABANDONED

NUCLEOTIDE AND PROTEIN SEQUENCES OF PROTEASE DOMAINS OF ENDOTHELIASE AND METHODS BASED THEREON (Endothelias 1 & 2 - MTSP 2 & 5)

UNITED KINGDOM	10-109-001AGB	CEQ			6/13/2007	EP 1 230 349	ISSUED
UNITED STATES	10-109-P001A	NEW	11/18/1999	60/166,391			ABANDONED
AUSTRALIA	10-109-001AAU	DCA	11/17/2000	16239/01	9/21/2006	784746	ABANDONED
CANADA	10-109-001ACA	DCA	11/17/2000	2,387,805	8/28/2012	2,387,805	ISSUED
EUROPEAN PATENT	10-109-001AEP	DCA	11/17/2000	00978819.1	6/13/2007	EP 1 230 349	ISSUED
IRELAND	10-109-001AIE	CEQ	11/17/2000	00978819.1	6/13/2007	1230349	ISSUED
ISRAEL	10-109-001AIL	DCA	11/17/2000	149340			ABANDONED
JAPAN	10-109-001AJP	DCA	11/17/2000	2001-538483			ABANDONED
SOUTH KOREA	10-109-001AKR	DCA	11/17/2000	10-2002-7006388			ABANDONED
NEW ZEALAND	10-109-001ANZ	DCA	11/17/2000	518407	5/10/2004	518407	ABANDONED
NEW ZEALAND	10-109-001ANZA	DIV	11/17/2000	529387	8/11/2005	529387	ABANDONED
RUSSIA	10-109-001ARU	DCA	11/17/2000	2002113076			ABANDONED
WIPO	10-109-001AWO	CEQ	11/17/2000	PCT/US00/31803		WO01/36604	NAT PHASE
SOUTH AFRICA	10-109-001AZA	DCA	11/17/2000	2002/3366	9/23/2003	2002/3366	ISSUED
UNITED STATES	10-109-001AUS	FCA	11/20/2000	09/717,473	10/2/2007	7,276,364	ISSUED

PLASMINOGEN ACTIVATOR INHIBITOR ANTAGONISTS

UNITED STATES	10-108-001AUS	NEW	11/19/1999	09/444,172	10/28/2003	6,638,977	ABANDONED
UNITED STATES	10-108-P001A	NEW	2/28/2000	60/185,564			ABANDONED
UNITED STATES	10-108-001AUSB	CIP	11/17/2000	09/716,036	1/13/2004	6,677,473	ISSUED

POTENT ANTIGEN PRESENTING CELL COMPOSITION

UNITED STATES	14-121-001US	NEW	7/12/1995	08/501,987	9/19/2000	6,121,044	ISSUED
AUSTRALIA	14-121-001AU	DCA	7/12/1996	64576/96	3/27/1999	701943	ISSUED
CANADA	14-121-001CA	DCA	7/12/1996	2,226,490			ABANDONED
EUROPEAN PATENT	14-121-001EP	DCA	7/12/1996	EP96923765.0			ABANDONED
JAPAN	14-121-001JP	DCA	7/12/1996	9-506009			ABANDONED
WIPO	14-121-001WO	CEQ	7/12/1996	PCT/US96/11640	1/30/1997	WO97/03186	NAT PHASE

Confidential

PATENT
REEL: 036126 FRAME: 0296

Dendreon Patent Portfolio Status Report

Patent Report by Invention

Printed: 01/15/2015

Page 24

COUNTRY	REFERENCE#	TYPE	FILED	SERIAL#	ISSUED	PATENT#	STATUS
RESIN DERIVATIZATION METHOD AND USES THEREOF							
UNITED STATES	10-113-003US	NEW	7/24/1998	09/122,576	9/7/2004	6,787,612	ISSUED
EUROPEAN PATENT	10-113-003EP	DCA	7/23/1999	99935908.6			ABANDONED
WIPO	10-113-003WO	CEQ	7/23/1999	PCT/US99/16828		WO00/05243	NAT PHASE
JAPAN	10-113-003JP	DCA	1/24/2001	2000-561199			ABANDONED

SUBSTITUTED 3-AMINO-2-HYDROXYPHENYLACETAMIDE DERIVATIVES AS ENZYME INHIBITORS (I)

UNITED STATES	10-103-017US	NEW	11/26/1997	08/980,114	1/4/2000	6,011,047	ISSUED
WIPO	10-103-018WO	DCA	11/23/1998	PCT/US98/25167		WO99/26920	ABANDONED

TRYPSIN INHIBITORS

UNITED STATES	10-117-001US	NEW	1/30/1992	07/828,388			ABANDONED
CANADA	10-117-001CA	DCA	1/29/1993	2,128,711	1/11/2005	2,128,711	ABANDONED
EUROPEAN PATENT	10-117-001EP	CEQ	1/29/1993	93905778.2	9/29/2004	0627925	ABANDONED
UNITED KINGDOM	10-117-001GB	DCA	1/29/1993	93905778.2	9/29/2004	0627925	ABANDONED
IRELAND	10-117-001IE	DCA	1/29/1993	93905778.2	9/29/2004	0627925	ABANDONED
JAPAN	10-117-001JP	DCA	1/29/1993	513488/1993			ABANDONED
UNITED STATES	10-117-001USA	CIP	1/29/1993	08/011,666	7/9/1996	5,534,498	EXPIRED
WIPO	10-117-001WO	DCA	1/29/1993	PCT/US93/00906		WO93/14779	NAT PHASE
UNITED STATES	10-117-001USB	CON	5/31/1995	08/455,974	2/3/1998	5,714,580	ISSUED

Confidential

RECORDED: 07/16/2015

PATENT
REEL: 036126 FRAME: 0297